

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : C12N 15/60, 5/10, 1/21, 9/88, C12Q 1/68, C07K 16/40, G01N 33/50, 33/68		A2	(11) International Publication Number: WO 99/16888
			(43) International Publication Date: 8 April 1999 (08.04.99)
(21) International Application Number: PCT/US98/20365 (22) International Filing Date: 29 September 1998 (29.09.98) (30) Priority Data: 08/939,309                      29 September 1997 (29.09.97)    US (71) Applicant: CHILDREN'S HOSPITAL OAKLAND RE- SEARCH INSTITUTE [US/US]; 747 Fifty Second Street, Oakland, CA 96409-1809 (US). (72) Inventors: SABA, Julie, D.; Apartment 7317, 6401 Bay Street, Emeryville, CA 95608 (US). ZHOU, Jianhui; 246 Bearritz Court, Redwood City, CA 94065 (US). (74) Agents: MAKI, David, J. et al.; Seed and Berry LLP, 6300 Columbia Center, 701 Fifth Avenue, Seattle, WA 98104-7092 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  Published <i>Without international search report and to be republished          upon receipt of that report.</i>	
(54) Title: SPHINGOSINE-1-PHOSPHATE LYASE POLYPEPTIDES, POLYNUCLEOTIDES AND MODULATING AGENTS AND METHODS OF USE THEREFOR			
(57) Abstract			
Compositions, methods and kits for diagnosing and treating cancer are provided. Therapeutic compositions may comprise agents that modulate the expression or activity of a sphingosine-1-phosphate lyase (SPL). Such compositions may be administered to a mammal afflicted with cancer. Diagnostic methods and kits may employ an agent suitable for detecting alterations in endogenous SPL. Such methods and kits may be used to detect the presence of a cancer or to evaluate the prognosis of a known disease. SPL polypeptides, polynucleotides and antibodies are also provided.			
<pre> GGT GAT GAT TTG ATC CAC TTA CAA ACA ATC CCA TAC GAA AAA TAT TGC      578 Gly Asp Asp Leu Ile His Leu Glu Thr Ile Ala Tyr Glu Lys Tyr Cys 180      185      190  GTT GCC AAT CAA TTA CAT CCC GAT GTC TTT GCT GGC GTA GAT AAA ATG      624 Val Ala Asn Glu Leu His Pro Asp Val Phe Pro Ala Val Arg Lys Met 195      200      206  GAA TCC GAA GTG GTT TCT ATG GTT TTA AGA ATG TTT AAT GGC CCT TCT      672 Glu Ser Glu Val Val Ser Met Val Leu Arg Met Phe Asn Ala Pro Ser 210      215      220  GAT ACA GGT TGT GGT ACC ACA ACT TCA GGT GGT ACA GAA TCC TTG CTT      720 Asp Thr Gly Cys Gly Thr Thr Thr Ser Gly Gly Thr Glu Ser Leu Leu 225      230      235      240  TTA GCA TGT CTG AGC GCT AAA ATG TAT GCC GTT CAT CAT GGT GGA ATC      768 Leu Ala Cys Leu Ser Ala Lys Met Tyr Ala Leu His His Arg Gly Ile 245      250      255  ACC GAA CCA GAA ATA ATT GCT CCC GTA ACT GCA CAT GGT GGG TTT GAC      816 Thr Glu Pro Glu Ile Ile Ala Pro Val Thr Ala His Ala Gly Phe Asp 260      265      270  AAA GCT GCT TAT TAC TTT GGC ATG AAG CTA GGC CAC GTG GAG CTA GAT      864 Lys Ala Ala Tyr Tyr Phe Gly Met Lys Leu Arg His Val Glu Leu Asp 275      280      285  CCA ACG ACA TAT CAA GTG GAC CTG GGA AAA GTG AAA AAA TTC ATC AAT      912 Pro Thr Thr Tyr Glu Val Asp Leu Gly Lys Val Lys Lys Phe Ile Asn 290      295      300  AAG AAC ACA ATT TTA CTG GTC GGT TCC GGT CCA AAG TTT GCT CAT GGT      960 Lys Asn Thr Ile Leu Leu Val Gly Ser Ala Pro Asn Phe Pro His Gly 305      310      315      320  ATT GCC GAT GAT ATT GAA GGA TTG GGT AAA ATA GCA CAA AAA TAT AAA      1008 Ile Ala Asp Asp Ile Glu Gly Leu Gly Lys Ile Ala Glu Lys Tyr Lys 325      330      335  CTT GCT TTA CAC GTC GAC AGT TGT CTA GGT TCC TTT ATT GTT TCA TTT      1056 Leu Pro Leu His Val Asp Ser Cys Leu Gly Ser Phe Ile Val Ser Phe 340      345      350 </pre>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						



DescriptionSPHINGOSINE-1-PHOSPHATE LYASE POLYPEPTIDES,  
POLYNUCLEOTIDES AND MODULATING AGENTS AND METHODS OF  
5 USE THEREFORTechnical Field

10 The present invention relates generally to cancer detection and therapy. The invention is more particularly related to sphingosine-1-phosphate lyase polynucleotides and polypeptides, and to agents that modulate the expression and/or activity of such polypeptides. Such agents may be used, for example, to diagnose and/or treat cancers such as breast cancer.

15 Background of the Invention

Breast cancer is a significant health problem for women in the United States and throughout the world. Although advances have been made in detection and treatment of the disease, breast cancer remains the most common form of cancer, and the second leading cause of cancer death, in American women. Among African-American women and women between 15 and 54 years  
20 of age, breast cancer is the leading cause of cancer death. One out of every eight women in the United States will develop breast cancer, a risk which has increased 52% during 1950-1990. In 1994, it is estimated that 182,000 new cases of female breast cancer were diagnosed, and 46,000 women died from the disease.

25 No vaccine or other universally successful method for the prevention or treatment of breast cancer is currently available. Management of the disease currently relies on a combination of early diagnosis (through routine breast screening procedures) and aggressive treatment, which may include one or more of a variety of treatments such as surgery, radiotherapy, chemotherapy and  
30 hormone therapy. The course of treatment for a particular breast cancer is often selected based on a variety of prognostic parameters, including an analysis of

specific tumor markers. However, the use of established markers often leads to a result that is difficult to interpret.

With current therapies, tumor invasiveness and metastasis is a critical determinant in the outcome for breast cancer patients. Although the five year survival for women diagnosed with localized breast cancer is about 90%, the five year survival drops to 18% for women whose disease has metastasized. Present therapies are inadequate for inhibiting tumor invasiveness for the large population of women with this severe disease.

Accordingly, improvements are needed in the treatment, diagnosis and prevention of breast cancer. The present invention fulfills this need and further provides other related advantages.

#### Summary of the Invention

Briefly stated, the present invention provides compositions and methods for the diagnosis and therapy of cancer. Within one aspect, the present invention provides isolated polynucleotides comprising a sequence selected from the group consisting of: (a) a sequence recited in SEQ ID NO:1; (b) a sequence recited in SEQ ID NO:3; (c) nucleotide sequences that hybridize to a polynucleotide complementary to either of the foregoing sequences under moderately stringent conditions, wherein the nucleotide sequences encode polypeptides having sphingosine-1-phosphate lyase activity; and (d) nucleotide sequences that encode a polypeptide encoded by any of the foregoing sequences.

Within a related aspect, an isolated polynucleotide is provided that encodes a polypeptide recited in SEQ ID NO:2, or a variant of such a polypeptide that has sphingosine-1-phosphate lyase activity. In another related aspect, an isolated polynucleotide comprising a sequence recited in SEQ ID NO:4, or a variant of such a polypeptide that has sphingosine-1-phosphate lyase activity, is provided.

Recombinant expression vectors comprising any of the foregoing polynucleotides, and host cells transformed or transfected with such expression vectors, are also provided.

Within further aspects, SPL polypeptides are provided. Such polypeptides may be encoded by any of the foregoing polynucleotides. Alternatively, a polypeptide may comprise an amino acid sequence recited in SEQ ID NO:2 or 4, or a variant thereof, wherein the polypeptide has sphingosine-1-phosphate lyase activity.

Within a further aspect, the present invention provides isolated polynucleotides comprising at least 100 nucleotides complementary to a sequence recited in SEQ ID NO:1 or 3.

Within other aspects, methods are provided for preparing a sphingosine-1-phosphate lyase, comprising culturing a host cell transformed or transfected with a polynucleotide as described above under conditions promoting expression of the polynucleotide and recovering a sphingosine-1-phosphate lyase.

In further aspects, the present invention provides methods for identifying an agent that modulates sphingosine-1-phosphate lyase activity. In one such aspect, the method comprises: (a) contacting a candidate agent with cells that express sphingosine-1-phosphate lyase; and (b) subsequently measuring the level of sphingosine-1-phosphate lyase or mRNA encoding sphingosine-1-phosphate lyase in the cells, relative to a predetermined level in the absence of candidate agent. Within another such aspect, the method comprises: (a) contacting a candidate agent with a polypeptide comprising a sequence recited in any one of SEQ ID NOs: 2, 4, 6 or 8, or a variant of such a sequence having sphingosine-1-phosphate lyase activity, wherein the step of contacting is carried out under conditions and for a time sufficient to allow the candidate modulator to interact with the polypeptide; and (b) subsequently measuring the ability of the polypeptide to degrade sphingosine-1-phosphate or a derivative thereof, relative to an ability in the absence of candidate agent. The step of contacting may be performed by incubating a cell expressing the polypeptide with the candidate modulator, and the step of measuring the ability to degrade sphingosine-1-phosphate may be performed using an *in vitro* assay and a cellular extract.

The present invention further provides pharmaceutical compositions comprising an agent that modulates sphingosine-1-phosphate lyase

activity in combination with a pharmaceutically acceptable carrier. Such agents preferably inhibit sphingosine-1-phosphate lyase activity. Such inhibition may be achieved by inhibiting expression of an endogenous SPL gene, or by inhibiting the ability of an endogenous SPL to degrade sphingosine-1-phosphate. Within certain  
5 preferred embodiments, a modulating agent comprises a polynucleotide or an antibody or an antigen-binding fragment thereof.

Within still further aspects, the present invention provides methods for modulating sphingosine-1-phosphate activity, comprising contacting a sphingosine-1-phosphate lyase with an effective amount of an agent that  
10 modulates sphingosine-1-phosphate lyase activity, wherein the step of contacting is performed under conditions and for a time sufficient to allow the agent and the sphingosine-1-phosphate lyase to interact. To modulate sphingosine-1-phosphate lyase activity in a cell, a cell expressing sphingosine-1-phosphate may be contacted with such an agent.

15 Within related aspects, the present invention provides methods for inhibiting the growth of a cancer cell, comprising contacting a cancer cell with an agent that inhibits sphingosine-1-phosphate lyase activity. In a preferred embodiment, the cancer cell is a breast cancer cell.

The present invention also provides methods for inhibiting the  
20 development and/or metastasis of a cancer in a mammal, comprising administering to a mammal an agent that inhibits sphingosine-1-phosphate lyase activity. Within certain embodiments, an agent may comprise, or be linked to, a targeting component, such as an anti-tumor antibody or a component that binds to an estrogen receptor.

25 Within other aspects, methods for diagnosing cancer in a mammal are provided, comprising detecting an alteration in an endogenous sphingosine-1-phosphate lyase gene in a sample obtained from a mammal, and therefrom diagnosing a cancer in the mammal. In certain embodiments the cancer is breast cancer and the sample is a breast tumor biopsy.

30 In related aspects, the present invention provides methods for evaluating a cancer prognosis, comprising determining the presence or absence of

an alteration in an endogenous sphingosine-1-phosphate lyase gene in a sample obtained from a mammal afflicted with cancer, and therefrom determining a prognosis.

The present invention further provides isolated antibodies that bind  
5 to a polypeptide having a sequence recited in any one of SEQ ID NOs: 2, 4 or 6. Such antibodies may be polyclonal or monoclonal, and may inhibit the ability of a polypeptide having a sequence recited in any one of SEQ ID NOs: 2, 4 or 6 to degrade sphingosine-1-phosphate.

In still further aspects, the present invention provides methods for  
10 detecting sphingosine-1-phosphate lyase in a sample, comprising: (a) contacting a sample with an antibody as described above under conditions and for a time sufficient to allow the antibody to bind to sphingosine-1-phosphate lyase; and (b) detecting in the sample the presence of sphingosine-1-phosphate lyase bound to the antibody.

15 Kits for use in the above methods are also provided. A kit for detecting sphingosine-1-phosphate lyase in a sample comprises an antibody as described above and a buffer or detection reagent. A kit for detecting an alteration in a sphingosine-1-phosphate gene in a sample comprises a polynucleotide and a detection reagent.

20 Within further aspects, the present invention provides transgenic animals in which sphingosine-1-phosphate lyase activity is reduced, and cell lines derived from such transgenic animals.

These and other aspects of the present invention will become apparent upon reference to the following detailed description and attached  
25 drawings. All references disclosed herein are hereby incorporated by reference in their entirety as if each was incorporated individually.

#### Brief Description of the Drawings

Figures 1A-1C present the sequence of a *S. cerevisiae*  
30 polynucleotide encoding a representative SPL polypeptide

Figures 2A and 2B present the sequence of a *C. elegans* polynucleotide encoding a representative SPL polypeptide.

Figures 3A and 3B present the sequence of a *Mus musculus* polynucleotide encoding a representative SPL polypeptide.

5 Figure 4 presents a comparison of the endogenous SPL genomic sequences from *C. elegans*, yeast and mouse.

Figure 5 is a photograph showing the growth of yeast cells grown to saturation in liquid culture and then plated on YPD with (top plate) and without (lower plate) 50µM sphingosine. On each plate, the top row of cells is BST1Δ (JS16, which is a variation of SGP3 (*leu2-3,112 trp1 ura3-52 his3 ade8* 10 *ras1::HIS3*) in which the *BST1* gene has been replaced by a G418-resistant marker, *NEO*). The second row is JS16 transformed with vector alone. The third row and the bottom two rows (mBST1) show JS60 cells (JS16[pYES-mouseSPL]) and the fourth row (ceBST1) shows JS61 cells (JS16[pYES2-*C. elegans*BST1]). 15 The fifth row on each plate (BST1-WT) shows the growth of the wildtype SGP3 strain.

Figure 6A is an autoradiogram showing the products of an SPL assay performed on extracts obtained from JS16 transformed with JS29=pYES2-yeast *BST1* (ytBST1), JS60=pYES2-mouseSPL (mBST1) or pYES2 without 20 insert (vehicle control). Figure 6B is a histogram depicting the activity in the strains shown in Figure 6A, as determined by scraping a TLC plate as shown in Figure 6A and assessing the level of radioactivity.

Figure 7 is an autoradiogram depicting the results of a Northern blot analysis of the level of mouse SPL in various mouse tissues, as indicated.

25 Figures 8A-8C present a sequence of a human polynucleotide encoding a representative SPL polypeptide.

#### Detailed Description of the Invention

30 As noted above, the present invention is generally directed to compositions and methods for the diagnosis and therapy of cancers such as breast cancer. The invention is more particularly related to sphingosine-1-phosphate

lyase (SPL) polypeptides, which have the ability to cleave sphingosine-1-phosphate into inactive metabolites, and to polynucleotides encoding such polypeptides. Sphingosine-1-phosphate is an endogenous tumor-suppressor lipid that potently inhibits breast cancer cell growth and invasiveness, while not affecting the growth of non-tumor cells (*see* Sadahira et al., *Proc. Natl. Acad. Sci. USA* 89:9686-90, 1992). *In vivo*, SPL catalyzes the cleavage of sphingosine-1-phosphate at the C<sub>2-3</sub> carbon bond to yield a long chain aldehyde and ethanolamine phosphate, the final step in the degradation of all higher order sphingolipids. Agents that decrease the expression or activity of endogenous SPL polypeptides are encompassed by the present invention. Such modulating agents may be identified using methods described herein and used, for example, in cancer therapy. It has also been found, within the context of the present invention, that the detection of alterations in an endogenous SPL sequence can be used to diagnose cancer, and to assess the prognosis for recovery. The present invention further provides such diagnostic methods and kits.

As used herein, the term "polypeptide" encompasses amino acid chains of any length, including full length endogenous (*i.e.*, native) SPL proteins and variants of endogenous sequences. "Variants" are polypeptides that differ in sequence from a native SPL only in substitutions, deletions and/or other modifications, such that the variant retains SPL activity, which may be determined using a representative method described herein. Within an SPL polypeptide variant, amino acid substitutions are preferably made at no more than 50% of the amino acid residues in the native polypeptide, and more preferably at no more than 25% of the amino acid residues. Such substitutions are preferably conservative. A conservative substitution is one in which an amino acid is substituted for another amino acid that has similar properties, such that one skilled in the art of peptide chemistry would expect the secondary structure and hydrophobic nature of the polypeptide to be substantially unchanged. In general, the following amino acids represent conservative changes: (1) ala, pro, gly, glu, asp, gln; asn, ser, thr; (2) cys, ser, tyr, thr; (3) val, ile, leu, met, ala, phe; (4) lys, arg, his; and (5) phe, tyr, trp, his. Substitutions, deletions and/or amino acid

additions may be made at any location(s) in the polypeptide, provided that the modification does not diminish the SPL activity of the variant. Thus, a variant may comprise only a portion of a native SPL sequence. In addition, or alternatively, variants may contain additional amino acid sequences (such as, for example, linkers, tags and/or ligands), preferably at the amino and/or carboxy termini. Such sequences may be used, for example, to facilitate purification, detection or cellular uptake of the polypeptide.

The SPL activity of an SPL polypeptide may generally be assessed using an *in vitro* assay that detects the degradation of labeled substrate (*i.e.*, sphingosine-1-phosphate, or a derivative thereof). Within such assays, pyridoxal 5'-phosphate is a requirement for SPL activity. In addition, the reaction generally proceeds optimally at pH 7.4-7.6 and requires chelators due to sensitivity toward heavy metal ions. The substrate should be a D-*erythro* isomer, but in derivatives of sphingosine-1-phosphate the type and chain length of sphingoid base may vary. In general, an assay as described by Van Veldhoven and Mannaerts, *J. Biol. Chem.* 266:12502-07, 1991 may be employed. Briefly, a solution (*e.g.*, a cellular extract) containing the polypeptide may be incubated with 40  $\mu$ M substrate at 37°C for 1 hour in the presence of, for example, 50 mM sucrose, 100 mM K-phosphate buffer pH 7.4, 25 mM NaF, 0.1% (w/v) Triton X-100, 0.5 mM EDTA, 2 mM DTT, 0.25 mM pyridoxal phosphate. Reactions may then be terminated and analyzed by thin-layer chromatography to detect the formation of labeled fatty aldehydes and further metabolites. In general, a polypeptide has SPL activity if, within such an assay: (1) the presence of 2 - 50  $\mu$ g polypeptide (or 0.1 - 10 mg/mL) results in a statistically significant increase in the level of substrate degradation, preferably a two-fold increase, relative to the level observed in the absence of polypeptide; and (2) the increase in the level of substrate degradation is pyridoxal 5'-phosphate dependent.

Within certain embodiments, an *in vitro* assay for SPL activity may be performed using cellular extracts prepared from cells that express the polypeptide of interest. Preferably, in the absence of a gene encoding an SPL polypeptide, such cells do not produce a significant amount of endogenous SPL



(i.e., a cellular extract should not contain a detectable increase in the level of SPL, as compared to buffer alone without extract). It has been found, within the context of the present invention, that yeast cells containing deletion of the SPL gene (*BST1*) are suitable for use in evaluating the SPL activity of a polypeptide.

5 *bst1*Δ cells can be generated from *S. cerevisiae* using standard techniques, such as PCR, as described herein. A polypeptide to be tested for SPL activity may then be expressed in *bst1*Δ cells, and the level of SPL activity in an extract containing the polypeptide may be compared to that of an extract prepared from cells that do not express the polypeptide. For such a test, a polypeptide is preferably expressed on  
10 a high-copy yeast vector (such as pYES2, which is available from Invitrogen) yielding more than 20 copies of the gene per cell. In general, a polypeptide has SPL activity if, when expressed using such a vector in a *bst1*Δ cell, a cellular extract results in a two-fold increase in substrate degradation over the level observed for an extract prepared from cells not expressing the polypeptide.

15 A further test for SPL activity may be based upon functional complementation in the *bst1*Δ strain. It has been found, within the context of the present invention, that *bst1*Δ cells are highly sensitive to *D-erythro*-sphingosine. In particular, concentrations as low as 10 μM sphingosine completely inhibit the growth of *bst1*Δ cells. Such a level of sphingosine has no effect on the growth of  
20 wildtype cells. A polypeptide having SPL activity as provided above significantly diminishes (i.e., by at least two fold) the sphingosine sensitivity when expressed on a high-copy yeast vector yielding more than 20 copies of the gene per cell.

In general, SPL polypeptides, and polynucleotides encoding such polypeptides, may be prepared using any of a variety of techniques that are well  
25 known in the art. For example, a DNA sequence encoding native SPL may be prepared by amplification from a suitable cDNA or genomic library using, for example, polymerase chain reaction (PCR) or hybridization techniques. Libraries may generally be prepared and screened using methods well known to those of ordinary skill in the art, such as those described in Sambrook et al., *Molecular*  
30 *Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratories, Cold Spring

Harbor, NY, 1989. cDNA libraries may be prepared from any of a variety of sources known to contain enzymes having SPL activity. SPL activity is ubiquitous with regard to species and mammalian tissues, with the exception of platelets, in which SPL activity is notably absent. In rat tissues, the highest levels of activity have been demonstrated in intestinal mucosa, liver and Harderian gland, with low activity in skeletal muscle and heart. Activity has also been demonstrated in a number of human (hepatoma cell line HB 8065, cervical carcinoma HeLa), mouse (hepatoma line BW1, mouse embryo 3T3-L1, Swiss 3T3 cells) and other cell lines, as well as in human cultured fibroblasts. Preferred cDNA libraries may prepared from human liver, intestine or brain tissues or cells. Other libraries that may be employed will be apparent to those of ordinary skill in the art. Primers for use in amplification may be readily designed based on the sequence of a native SPL polypeptide or polynucleotide, as provided herein.

Alternatively, an endogenous SPL gene may be identified using a screen for cDNAs that complement the *BST1* deletion in yeast. A cDNA expression library may be generated using a regulatable yeast expression vector (e.g., pYES, which is available from Invitrogen, Inc.) and standard techniques. A yeast *bst1* $\Delta$  strain may then be transformed with the cDNA library, and endogenous cDNAs having the ability to functionally complement the yeast lyase defect (i.e., restore the ability to grow in the presence of D-erythro-sphingosine) may be isolated.

An endogenous SPL gene may also be identified based on cross-reactivity of the protein product with anti-SPL antibodies, which may be prepared as described herein. Such screens may generally be performed using standard techniques (see Huynh et al., "Construction and Screening cDNA Libraries in  $\lambda$ gt11," in D.M. Glover, ed., *DNA Cloning: A Practical Approach*, 1:49-78, 1984 (IRL Press, Oxford)).

Polynucleotides encompassed by the present invention include DNA and RNA molecules that comprise an endogenous SPL gene sequence. Such polynucleotides include those that comprise a sequence recited in any one of SEQ ID NOs:1, 3, 5 and 7. Also encompassed are other polynucleotides that

encode an SPL amino acid sequence provided in any one of SEQ ID NOs: 2, 4, 6 and 8, as well as polynucleotides that encode variants of a native SPL sequence that retain SPL activity. Polynucleotides that are substantially homologous to a sequence complementary to an endogenous SPL gene are also within the scope of the present invention. "Substantial homology," as used herein refers to polynucleotides that are capable of hybridizing under moderately stringent conditions to a polynucleotide complementary to a sequence provided in SEQ ID NO:1 or SEQ ID NO:3, provided that the encoded SPL polypeptide variant retains SPL activity. Suitable moderately stringent conditions include prewashing in a solution of 5X SSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0); hybridizing at 50-65°C, 5X SSC, overnight; followed by washing twice at 65°C for 20 minutes with each of 2X, 0.5X and 0.2X SSC containing 0.1% SDS. Nucleotide sequences that, because of code degeneracy, encode a polypeptide encoded by any of the above sequences are also encompassed by the present invention.

Polypeptides of the present invention may be prepared by expression of recombinant DNA encoding the polypeptide in cultured host cells. Preferably, the host cells are bacteria, yeast, insect or mammalian cells, and more preferably the host cells are *S. cerevisiae* *bst1*Δ cells. The recombinant DNA may be cloned into any expression vector suitable for use within the host cell and transfected into the host cell using techniques well known to those of ordinary skill in the art. A suitable expression vector contains a promoter sequence that is active in the host cell. A tissue-specific or conditionally active promoter may also be used. Preferred promoters express the polypeptide at high levels.

Optionally, the construct may contain an enhancer, a transcription terminator, a poly(A) signal sequence, a bacterial or mammalian origin of replication and/or a selectable marker, all of which are well known in the art. Enhancer sequences may be included as part of the promoter region or separately. Transcription terminators are sequences that stop RNA polymerase-mediated transcription. The poly(A) signal may be contained within the termination sequence or incorporated separately. A selectable marker includes any gene that confers a phenotype on the host cell that allows transformed cells to be identified.

Such markers may confer a growth advantage under specified conditions. Suitable selectable markers for bacteria are well known and include resistance genes for ampicillin, kanamycin and tetracycline. Suitable selectable markers for mammalian cells include hygromycin, neomycin, genes that complement a  
5 deficiency in the host (*e.g.*, thymidine kinase and TK<sup>-</sup>cells) and others well known in the art. For yeast cells, one suitable selectable marker is URA3, which confers the ability to grow on medium without uracil.

DNA sequences expressed in this manner may encode a native SPL polypeptide (*e.g.*, human), or may encode portions or other variants of native SPL  
10 polypeptide. DNA molecules encoding variants of a native SPL may generally be prepared using standard mutagenesis techniques, such as oligonucleotide-directed site-specific mutagenesis, and sections of the DNA sequence may be removed to permit preparation of truncated polypeptides.

To generate cells that express a polynucleotide encoding an SPL  
15 polypeptide, cells may be transfected using any of a variety of techniques known in the art. Such transfection may result in stable transformants or may be transient. One suitable transfection technique is electroporation, which may be performed on a variety of cell types, including mammalian cells, yeast cells and bacteria, using commercially available equipment. Optimal conditions for  
20 electroporation (including voltage, resistance and pulse length) are experimentally determined for the particular host cell type, and general guidelines for optimizing electroporation may be obtained from manufacturers. Other suitable methods for transfection will depend upon the type of cell used (*e.g.*, the lithium acetate method for yeast), and will be apparent to those of ordinary skill in the art.  
25 Following transfection, cells may be maintained in conditions that promote expression of the polynucleotide within the cell. Appropriate conditions depend upon the expression system and cell type, and will be apparent to those skilled in the art.

SPL polypeptides may be expressed in transfected cells by  
30 culturing the cell under conditions promoting expression of the transfected polynucleotide. Appropriate conditions will depend on the specific host cell and

expression vector employed, and will be readily apparent to those of ordinary skill in the art. For commercially available expression vectors, the polypeptide may generally be expressed according to the manufacturer's instructions. For certain purposes, expressed polypeptides of this invention may be isolated in substantially  
5 pure form. Preferably, the polypeptides are isolated to a purity of at least 80% by weight, more preferably to a purity of at least 95% by weight, and most preferably to a purity of at least 99% by weight. In general, such purification may be achieved using, for example, the standard techniques of ammonium sulfate fractionation, SDS-PAGE electrophoresis, and/or affinity chromatography.

10 The present invention further provides antibodies that bind to an SPL polypeptide. Antibodies may function as modulating agents (as discussed further below) to inhibit or block SPL activity *in vivo*. Alternatively, or in addition, antibodies may be used within screens for endogenous SPL polypeptides or modulating agents, for purification of SPL polypeptides, for assaying the level  
15 of SPL within a sample and/or for studies of SPL expression. Such antibodies may be polyclonal or monoclonal, and are generally specific for one or more SPL polypeptides and/or one or more variants thereof. Within certain preferred embodiments, antibodies are polyclonal.

Antibodies may be prepared by any of a variety of techniques  
20 known to those of ordinary skill in the art (*see, e.g.,* Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988). In one such technique, an immunogen comprising an SPL polypeptide or antigenic portion thereof is initially injected into a suitable animal (*e.g.,* mice, rats, rabbits, sheep and goats), preferably according to a predetermined schedule incorporating one or  
25 more booster immunizations. The use of rabbits is preferred. To increase immunogenicity, an immunogen may be linked to, for example, glutaraldehyde or keyhole limpet hemocyanin (KLH). Following injection, the animals are bled periodically to obtain post-immune serum containing polyclonal anti-SPL antibodies. Polyclonal antibodies may then be purified from such antisera by, for  
30 example, affinity chromatography using an SPL polypeptide or antigenic portion

thereof coupled to a suitable solid support. Such polyclonal antibodies may be used directly for screening purposes and for Western blots.

More specifically, an adult rabbit (*e.g.*, NZW) may be immunized with 10  $\mu$ g purified (*e.g.*, using a nickel-column) SPL polypeptide emulsified in complete Freund's adjuvant (1:1 v/v) in a volume of 1mL. Immunization may be achieved via injection in at least six different subcutaneous sites. For subsequent immunizations, 5  $\mu$ g of an SPL polypeptide may be emulsified in in complete Freund's adjuvant and injected in the same manner. Immunizations may continue until a suitable serum antibody titer is achieved (typically a total of about three immunizations). The rabbit may be bled immediately before immunization to obtain pre-immune serum, and then 7-10 days following each immunization.

For certain embodiments, monoclonal antibodies may be desired. Monoclonal antibodies may be prepared, for example, using the technique of Kohler and Milstein, *Eur. J. Immunol.* 6:511-519, 1976, and improvements thereto. Briefly, these methods involve the preparation of immortal cell lines capable of producing antibodies having the desired specificity (*i.e.*, reactivity with the polypeptide of interest). Such cell lines may be produced, for example, from spleen cells obtained from an animal immunized as described above. The spleen cells are then immortalized by, for example, fusion with a myeloma cell fusion partner, preferably one that is syngeneic with the immunized animal. For example, the spleen cells and myeloma cells may be combined with a nonionic detergent for a few minutes and then plated at low density on a selective medium that supports the growth of hybrid cells, but not myeloma cells. A preferred selection technique uses HAT (hypoxanthine, aminopterin, thymidine) selection. After a sufficient time, usually about 1 to 2 weeks, colonies of hybrids are observed. Single colonies are selected and tested for binding activity against the polypeptide. Hybridomas having high reactivity and specificity are preferred.

Monoclonal antibodies may be isolated from the supernatants of growing hybridoma colonies. In addition, various techniques may be employed to enhance the yield, such as injection of the hybridoma cell line into the peritoneal cavity of a suitable vertebrate host, such as a mouse. Monoclonal antibodies may

then be harvested from the ascites fluid or the blood. Contaminants may be removed from the antibodies by conventional techniques, such as chromatography, gel filtration, precipitation, and extraction.

As noted above, the present invention provides agents that  
5 modulate, preferably inhibit, the expression (transcription or translation), stability and/or activity of an SPL polypeptide. To identify such a modulating agent, any of a variety of screens may be performed. Candidate modulating agents may be obtained using well known techniques from a variety of sources, such as plants, fungi or libraries of chemicals, small molecules or random peptides. Antibodies  
10 that bind to an SPL polypeptide, and anti-sense polynucleotides that hybridize to a polynucleotides that encodes an SPL, may be candidate modulating agents. Preferably, a modulating agent has a minimum of side effects and is non-toxic. For some applications, agents that can penetrate cells are preferred.

Screens for modulating agents that decrease SPL expression or  
15 stability may be readily performed using well known techniques that detect the level of SPL protein or mRNA. Suitable assays include RNase protection assays, *in situ* hybridization, ELISAs, Northern blots and Western blots. Such assays may generally be performed using standard methods (*see* Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratories, Cold Spring  
20 Harbor, NY, 1989). For example, to detect mRNA encoding SPL, a nucleic acid probe complementary to all or a portion of the SPL gene sequence may be employed in a Northern blot analysis of mRNA prepared from suitable cells. To detect SPL protein, a reagent that binds to the protein (typically an antibody, as described herein) may be employed within an ELISA or Western assay.  
25 Following binding, a reporter group suitable for direct or indirect detection of the reagent is employed (*i.e.*, the reporter group may be covalently bound to the reagent or may be bound to a second molecule, such as Protein A, Protein G, immunoglobulin or lectin, which is itself capable of binding to the reagent). Suitable reporter groups include, but are not limited to, enzymes (*e.g.*, horseradish  
30 peroxidase), substrates, cofactors, inhibitors, dyes, radionuclides, luminescent groups, fluorescent groups and biotin. Such reporter groups may be used to

directly or indirectly detect binding of the reagent to a sample component using standard methods known to those of ordinary skill in the art.

To use such assays for identifying a modulating agent, the level of SPL protein or mRNA may be evaluated in cells treated with one or more candidate modulating agents. An increase or decrease in SPL levels may be measured by evaluating the level of SPL mRNA and/or protein in the presence and absence of candidate modulating agent. For example, an antisense modulating agent may be evaluated by assaying the effect on SPL levels. Suitable cells for use in such assays include the breast cancer cell lines MCF-7 (ATCC Accession Number HTB-22) and MDA-MB-231 (ATCC Accession Number HTB-26). A candidate modulator may be tested by transfecting the cells with a polynucleotide encoding the candidate and evaluating the effect of expression of the polynucleotide on SPL levels. Alternatively, the cells may be contacted with a candidate modulator, typically in an amount ranging from about 10 nM to about 10 mM. A candidate that results in a statistically significant change in the level of SPL mRNA and/or protein is a modulating agent.

Alternatively, or in addition, a candidate modulating agent may be tested for the ability to inhibit SPL activity, using an *in vitro* assay as described herein (see Van Veldhoven and Mannaerts, *J. Biol. Chem.* 266:12502-07, 1991) that detects the degradation of labeled substrate (*i.e.*, sphingosine-1-phosphate, or a derivative thereof). Briefly, a solution (*e.g.*, a cellular extract) containing an SPL polypeptide (*e.g.*, 10 nM to about 10 mM) may be incubated with a candidate modulating agent (typically 1 nM to 10 mM, preferably 10 nM to 1 mM) and a substrate (*e.g.*, 40  $\mu$ M) at 37°C for 1 hour in the presence of, for example, 50 mM sucrose, 100 mM K-phosphate buffer pH 7.4, 25 mM NaF, 0.1% (w/v) Triton X-100, 0.5 mM EDTA, 2 mM DTT, 0.25 mM pyridoxal phosphate. Reactions may then be terminated and analyzed by thin-layer chromatography to detect the formation of labeled fatty aldehydes and further metabolites. A modulating agent (*e.g.*, an antibody) that inhibits SPL activity results in a statistically significant decrease in the degradation of sphingosine-1-phosphate, relative to the level of



degradation in the absence of modulating agent. Such modulating agents may be used to inhibit SPL activity in a cell culture or a mammal, as described below.

A modulating agent may additionally comprise, or may be associated with, a targeting component that serves to direct the agent to a desired  
5 tissue or cell type. As used herein, a "targeting component" may be any substance (such as a compound or cell) that, when linked to a compound enhances the transport of the compound to a target tissue, thereby increasing the local concentration of the compound. Targeting components include antibodies or fragments thereof, receptors, ligands and other molecules that bind to cells of,  
10 in the vicinity of, the target tissue. Known targeting components include hormones, antibodies against cell surface antigens, lectins, adhesion molecules, tumor cell surface binding ligands, steroids, cholesterol, lymphokines, fibrinolytic enzymes and other drugs and proteins that bind to a desired target site. In particular, anti-tumor antibodies and compounds that bind to an estrogen receptor  
15 may serve as targeting components. An antibody employed in the present invention may be an intact (whole) molecule, a fragment thereof, or a functional equivalent thereof. Examples of antibody fragments are F(ab')<sub>2</sub>, -Fab', Fab and F[v] fragments, which may be produced by conventional methods or by genetic or protein engineering. Linkage may be via any suitable covalent bond using  
20 standard techniques that are well known in the art. Such linkage is generally covalent and may be achieved by, for example, direct condensation or other reactions, or by way of bi- or multi-functional linkers.

For *in vivo* use, a modulating agent as described herein is generally incorporated into a pharmaceutical composition prior to administration. A  
25 pharmaceutical composition comprises one or more modulating agents in combination with a physiologically acceptable carrier. To prepare a pharmaceutical composition, an effective amount of one or more modulating agents is mixed with any pharmaceutical carrier(s) known to those skilled in the art to be suitable for the particular mode of administration. A pharmaceutical  
30 carrier may be liquid, semi-liquid or solid. Solutions or suspensions used for parenteral, intradermal, subcutaneous or topical application may include, for

example, a sterile diluent (such as water), saline solution, fixed oil, polyethylene glycol, glycerine, propylene glycol or other synthetic solvent; antimicrobial agents (such as benzyl alcohol and methyl parabens); antioxidants (such as ascorbic acid and sodium bisulfite) and chelating agents (such as ethylenediaminetetraacetic acid (EDTA)); buffers (such as acetates, citrates and phosphates). If administered intravenously, suitable carriers include physiological saline or phosphate buffered saline (PBS), and solutions containing thickening and solubilizing agents, such as glucose, polyethylene glycol, polypropylene glycol and mixtures thereof. In addition, other pharmaceutically active ingredients (including other anti-cancer agents) and/or suitable excipients such as salts, buffers and stabilizers may, but need not, be present within the composition.

A modulating agent may be prepared with carriers that protect it against rapid elimination from the body, such as time release formulations or coatings. Such carriers include controlled release formulations, such as, but not limited to, implants and microencapsulated delivery systems, and biodegradable, biocompatible polymers, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, polyorthoesters, polylactic acid and others known to those of ordinary skill in the art.

Administration may be achieved by a variety of different routes, including oral, parenteral, nasal, intravenous, intradermal, subcutaneous or topical. Preferred modes of administration depend upon the nature of the condition to be treated or prevented. An amount that, following administration, inhibits, prevents or delays the progression and/or metastasis of a cancer is considered effective. Preferably, the amount administered is sufficient to result in regression, as indicated by 50% mass or by scan dimensions. The precise dosage and duration of treatment is a function of the disease being treated and may be determined empirically using known testing protocols or by testing the compositions in model systems known in the art and extrapolating therefrom. Controlled clinical trials may also be performed. Dosages may also vary with the severity of the condition to be alleviated. A pharmaceutical composition is generally formulated and administered to exert a therapeutically useful effect

while minimizing undesirable side effects. The composition may be administered one time, or may be divided into a number of smaller doses to be administered at intervals of time. For any particular subject, specific dosage regimens may be adjusted over time according to the individual need.

5 As an alternative to direct administration of a modulating agent, a polynucleotide encoding a modulating agent may be administered. Such a polynucleotide may be present in a pharmaceutical composition within any of a variety of delivery systems known to those of ordinary skill in the art, including nucleic acid, bacterial and viral expression systems, and colloidal dispersion  
10 systems such as liposomes. Appropriate nucleic acid expression systems contain the necessary DNA sequences for expression in the patient (such as a suitable promoter and terminating signal, as described above). The DNA may also be "naked," as described, for example, in Ulmer et al., *Science* 259:1745-49, 1993.

Various viral vectors that can be used to introduce a nucleic acid  
15 sequence into the targeted patient's cells include, but are not limited to, vaccinia or other pox virus, herpes virus, retrovirus, or adenovirus. Techniques for incorporating DNA into such vectors are well known to those of ordinary skill in the art. Another delivery system for polynucleotides is a colloidal dispersion system. Colloidal dispersion systems include macromolecule complexes,  
20 nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. The preparation and use of liposomes is well known to those of ordinary skill in the art.

Within certain aspects of the present invention, one or more modulating agents may be used to modulate SPL expression and/or activity *in*  
25 *vitro*, in a cell or in a mammal. *In vitro*, an SPL polypeptide may be contacted with a modulating agent that inhibits SPL activity (*e.g.*, certain antibodies). For use within a cell or a mammal, such modulation may be achieved by contacting a target cell with an effective amount of a modulating agent, as described herein. Administration to a mammal may generally be achieved as described above.

30 As noted above, inhibition of SPL expression and/or activity provides a method for inhibiting the growth (*i.e.*, proliferation) of a cancer cell,

either in culture or in a mammal afflicted with cancer. *In vivo*, such inhibition may also be used to inhibit cancer development, progression and/or metastasis. Accordingly, one or more modulating agents as provided herein may be administered as described above to a mammal in need of anti-cancer therapy.

5 Patients that may benefit from administration of a modulating agent are those afflicted with cancer. Such patients may be identified based on standard criteria that are well known in the art. Within preferred embodiments, a patient is afflicted with breast cancer, as identified based on tissue biopsy and microscopic evaluation, using techniques well known in the art. In particular, patients whose

10 tumor cells contain a tissue-specific deletion and/or alteration within an endogenous SPL gene may benefit from administration of a modulating agent, as provided herein.

Within other aspects, the present invention provides methods and kits for diagnosing cancer and/or identifying individuals with a risk for metastasis

15 that is higher or lower than average. It has been found, within the context of the present invention, that certain human tumor cells contain an altered SPL gene. In particular, certain brain tumor cells contain a deletion of residues 354 to 433 of the human SPL sequence indicated in Figure 8 and SEQ ID NO:4. Specific alterations present in other tumor cells, such as breast tumor cells, may be readily

20 identified using standard techniques, such as PCR. Alterations that may be associated with a particular tumor include amino acid deletions, insertions, substitutions and combinations thereof. Methods in which the presence or absence of such an alteration is determined may generally be used to detect cancer and to evaluate the prognosis for a patient known to be afflicted with cancer.

25 To detect an altered SPL gene, any of a variety of well-known techniques may be used including, but not limited to, PCR and hybridization techniques. Any sample that may contain cancerous cells may be assayed. In general, suitable samples are tumor biopsies. Within a preferred embodiment, a sample is a breast tumor biopsy.

30 Kits for diagnosing or evaluating the prognosis of a cancer generally comprise reagents for use in the particular assay to be employed. In

general, a kit of the present invention comprises one or more containers enclosing elements, such as probes, reagents or buffers, to be used in an assay. For example, a kit may contain one or more polynucleotide probes comprising at least 100 nucleotides, and preferably at least 200 nucleotides, complementary to an SPL mRNA. Such probe(s) may be used to detect an altered SPL gene by hybridization. For example, a kit may contain one probe that hybridizes to a region of an SPL gene that is not generally altered in tumors (a control) and a second probe that hybridizes to a region commonly deleted in breast cancer. A sample that contains mRNA that hybridizes to the first probe, and not to the second (using standard techniques) contains an altered SPL gene. Suitable control probes include probes that hybridize to a portion of the SPL gene outside of the commonly deleted region encoding amino acid residues 354 to 433; suitable probes for an altered region include probes that hybridize to a portion of the SPL gene that encodes amino acid residues 354 to 433. Alternatively, a kit may comprise one or more primers for PCR analyses, which may be readily designed based upon the sequences provided herein by those of ordinary skill in the art. Optionally, a kit may further comprise one or more solutions, compounds or detection reagents for use within an assay as described above.

In a related aspect of the present invention, kits for detecting SPL are provided. Such kits may be designed for detecting the level of SPL or nucleic acid encoding SPL within a sample, or may detect the level of SPL activity as described herein. A kit for detecting the level of SPL, or nucleic acid encoding SPL, typically contains a reagent that binds to the SPL protein, DNA or RNA. To detect nucleic acid encoding SPL, the reagent may be a nucleic acid probe or a PCR primer. To detect SPL protein, the reagent is typically an antibody. The kit may also contain a reporter group suitable for direct or indirect detection of the reagent as described above.

Within further aspects, the present invention provides transgenic mammals in which SPL activity is reduced, compared to a wild-type animal. Such animals may contain an alteration, insertion or deletion in an endogenous SPL gene, or may contain DNA encoding a modulating agent that inhibits

expression or activity of an SPL gene. Transgenic animals may be generated using techniques that are known to those of ordinary skill in the art. For example, a transgenic animal containing an insertion or deletion in the coding region for the SPL gene may be generated from embryonic stem cells, using standard techniques. Such stem cells may be generated by first identifying the full genomic sequence of the gene encoding the SPL, and then creating an insertion or deletion in the coding region in embryonic stem cells. Alternatively, appropriate genetically altered embryonic stem cells may be identified from a bank. Using the altered stem cells, hybrid animals may be generated with one normal SPL gene and one marked, abnormal gene. These hybrids may be mated, and homozygous progeny identified.

Transgenic animals may be used for a variety of purposes, which will be apparent to those of ordinary skill in the art. For example, such animals may be used to prepare cell lines from different tissues, using well known techniques. Such cell lines may be used, for example, to evaluate the effect of the alteration, and to test various candidate modulators.

#### Summary of Sequence Listing

- SEQ ID NO:1 is cDNA sequence encoding mouse endogenous SPL.
- SEQ ID NO:2 is amino acid sequence of mouse endogenous SPL.
- SEQ ID NO:3 is cDNA sequence encoding human endogenous SPL.
- SEQ ID NO:4 is amino acid sequence of human endogenous SPL.
- SEQ ID NO:5 is cDNA sequence encoding *C. elegans* endogenous SPL.
- SEQ ID NO:6 is amino acid sequence of *C. elegans* endogenous SPL.
- SEQ ID NO:7 is cDNA sequence encoding yeast endogenous SPL.
- SEQ ID NO:8 is amino acid sequence of yeast endogenous SPL.
- SEQ ID NO:9 is cDNA sequence encoding an altered human SPL.

SEQ ID NO:10 is amino acid sequence of an altered human SPL.

The following Examples are offered by way of illustration and not  
by way of limitation.

## EXAMPLES

Example 1Isolation and Characterization of SPL cDNA from Yeast

5 This Example illustrates the preparation of an *S. cerevisiae* cDNA molecule encoding an endogenous SPL polypeptide.

Wild-type yeast cells (SGP3 (Garrett and Broach, *Genes and Dev.* 3:1336-1348, 1989); *leu2-3,112 trp1 ura3-52 his3 ade8 ras1::HIS3*) were transformed with a yeast genomic library carried on the pRS202 high-copy shuttle  
10 vector (Sikorski and Heiter, *Genetics* 122:19-27, 1989) containing a selectable nutritional marker (*URA3*). pRS202 is a modified version of the pRS306 vector, into which a 2 micron plasmid piece was inserted. Inserts from this library are approximately 6-8 kb in length. Wild type yeast were transformed with the high copy library as described by Ito et al., *J. Bact.* 153:163-68, 1983, selected for  
15 uracil prototrophy (*i.e.*, the ability to grow on medium lacking uracil), and transformants were pooled and replated at a concentration of  $10^6$  cells per plate onto 1 mM D-erythro-sphingosine plates.

Six transformants which grew large colonies on 1mM D-erythro-sphingosine plates were grown in selective medium, and control SGP3 colonies  
20 were grown in minimal medium, at 30°C until saturated. Absorbance at 660 nm was used to correct for small variations in cell concentration between cultures. Serial dilutions were performed, and cells were template-inoculated onto 1 mM D-erythro-sphingosine plates and incubated at 30°C for 48 hours.

The most highly represented insert, 13-1, was subcloned and  
25 sequenced, and named *BST1* (bestower of sphingosine tolerance; GenBank accession number U51031; *Saccharomyces cerevisiae* genome database accession number YDR294C). The *BST1* nucleotide sequence encodes a previously unknown predicted protein of 65,523 kilodaltons and 589 amino acids in length. This sequence is 23% identical to *gadA* and *gadB*, two nearly identical *E. coli*  
30 genes encoding glutamate decarboxylase (GAD), a pyridoxal-5'-phosphate-dependent enzyme which catalyzes synthesis of the neurotransmitter  $\gamma$ -amino



butyric acid. *BST1* has been localized to *S. cerevisiae* chromosome 4. The sequence of *BST1* is provided in Figure 1 and SEQ ID NO:7.

To explore the function of *BST1*, a deletion strain was created through homologous recombination using a *NEO* selectable marker (Wach et al.,  
5 *Yeast* 10:1793-1808, 1994). Genomic *BST1* was replaced with *kanMX* (Wach et al., *Yeast* 10:1793-1808, 1994), which confers resistance to G418. Disruption was confirmed using PCR amplification of genomic DNA from G418 resistant clones, using primers to genomic sequence just 5' and 3' to the region replaced by the disruption. Deletion of *BST1* and all subsequent biological studies were  
10 performed in both SGP3 and in JK93d (Hietman et al., *Proc. Natl. Acad. Sci. USA* 88:1948-52, 1991); *ura3-52 leu2-3,112 his4 trp1 rme1*). Heterozygous diploids were sporulated, and spores segregated 2:2 for G418 resistance. Both G418 resistant and sensitive progeny were viable, indicating that *BST1* is not an essential gene.

15 Analysis of GAD activity in cytosolic extracts from wild type, *BST1* overexpression and *bst1Δ* strains indicated that *BST1* does not encode the *S. cerevisiae* homologue of GAD. However, deletion of *BST1* was associated with severe sensitivity to D-erythro-sphingosine. Concentrations as low as 10 μM sphingosine completely inhibited growth of *bst1Δ* strains but had no effect on the  
20 viability of wild type cells. In comparison to the control strain, the *bst1Δ* strain also demonstrated greater sensitivity to 100 μM phytosphingosine, the long chain base endogenous to *S. cerevisia*. No difference between the growth of wild type and *BST1* overexpression strains on phytosphingosine, which is only minimally toxic to wild type cells at this concentration, was observed.

25 To determine whether differences in sphingosine uptake or metabolism were responsible for these sensitivity differences, *BST1* wild type, overexpression and *bst1Δ* strains were exposed to [C3-<sup>3</sup>H]labeled sphingosine (American Radiolabeled Chemical, Inc., St. Louis, MO), washed in sterile water and subjected to Bligh-Dyer extractions (Bligh and Dyer, *Can. J. Buichem.*  
30 *Physiol.* 37:911-17, 1959). There were no major differences in sphingosine

recovery among the three strains. However, the aqueous phase from the *bst1* $\Delta$  strain contained a ten-fold increase in radioactivity over that of control and *BST1* overexpression strains. Thin layer chromatography (TLC) analysis of the lipid fractions in butanol:acetic acid:water (3:1:1) revealed a sphingosine band which appeared equivalent in each strain.

Radioactive sphingosine-1-phosphate (S-1-P) was also observed in the extracts from the *bst1* $\Delta$  strain, but not in the wild type or *BST1* overexpression strains. This compound accumulated rapidly, reaching a plateau by 60 minutes. Three separate TLC conditions were used to confirm the presence of S-1-P. These conditions, along with the resulting RF values, are shown below:

	butanol:water:acetic acid (3:1:1)
	.47
	chloroform:methanol:water (60:35:8)
15	.22
	chloroform:methanol:water:acetic acid (30:30:2:5)
	.33

Hyperaccumulation of S-1-P and hypersensitivity to D-erythro-sphingosine suggest a failure to metabolize S-1-P, indicating that *BST1* is a yeast SPL. To confirm this identification, lyase activity in *BST1* wild type, overexpression and deletion strains were evaluated as described by Veldhoven and Mannaerts, *J. Biol. Chem.* 266:12502-07, 1991, using unlabeled D-erythro-dihydrosphingosine-1-phosphate (Biomol, Plymouth Meeting, PA) and D-erythro-dihydrosphingosine [4,5-<sup>3</sup>H]1-phosphate (American Radiolabeled Chemicals, Inc., St. Louis, MO). Specific activity was 100 mCi/mmol. SPL activity was found to correlate with *BST1* expression, confirming *BST1* to be the yeast homologue of sphingosine-1-phosphate lyase.

These results indicate that *BST1* is a yeast SPL, and that SPL catalyzes a rate-limiting step in sphingolipid catabolism. Regulation of SPL activity may therefore result in regulation of intracellular S-1-P levels.

5

### Example 2

#### Isolation and Characterization of SPL cDNA from *C. elegans* and Mouse

This Example illustrates the identification of endogenous SPL cDNAs from *C. elegans* and *Mus musculus*.

10        Comparison of the yeast *BST1* sequence to sequences within the GenBank database identified a full length gene from *C. elegans* that was identified during the systematic sequencing of the *C. elegans* genome. This sequence was found to encode SPL, and is shown in Figure 2 and SEQ ID NOs:5 and 6. This and other DNA homology searches described herein were performed  
15        via the National Center for Biotechnology Information website using BLAST search program.

      Using both *S. cerevisiae* and *C. elegans* SPL sequences to search the EST database, an expressed sequence tag from early embryonic cells of the mouse (day 8 embryo, strain C57BL/6J) was identified. The cDNA clone  
20        containing this putative mouse SPL was purchased from Genome Systems, Inc (St. Louis, MO). Completion of the full length cDNA sequence revealed an 1709 bp open reading frame (Figure 3 and SEQ ID NOs:1 and 2). This mouse sequence showed significant homology to *BST1* and to other pyridoxal phosphate-binding enzymes such as glutamate decarboxylase, with greatest conservation surrounding  
25        the predicted pyridoxal phosphate-binding lysine (Figure 4). Since the two genes encoding mouse glutamate decarboxylase have been identified previously, and the identified sequence was unique and had no known function, it was a likely candidate mouse SPL gene.

      To confirm the SPL activity of the mouse gene, a two step process  
30        was undertaken. First, the sequence was cloned into the high-copy yeast expression vector, pYES2 (Invitrogen, Inc., Carlsbad, CA), in which the gene of

interest is placed under control of the yeast GAL promoter and is, therefore, transcriptionally activated by galactose and repressed by glucose. pYES2 also contains the *URA3* gene (which provides transformants the ability to grow in media without uracil) and an ampicillin resistance marker and origin of replication  
5 functional in *E. coli*.

The expression vector containing the full-length mouse SPL gene was then introduced into the yeast *bst1Δ* strain whichn as noted above, is extremely sensitive to D-erythro-sphingosine, as a result of metabolism of sphingosine to S-1-P. S-1-P cannot be further degraded in the absence of SPL  
10 activity and overaccumulates, causing growth inhibition. Transformation was performed using the lithium acetate method (Ito et al., *J. Bact.* 153:163-68, 1983). Transformants were grown on medium containing 20g/L galactose and selected for uracil prototrophy.

Transformants were then evaluated for sphingosine resistance.  
15 Strains of interest were grown to saturation in liquid culture for 2-3 days. They were then resuspended in minimal medium, placed in the first row of a 96-well plate and diluted serially from 1:2 to 1:4000 across the plate. The cultures were then template inoculated onto a control plate (YPD) and a plate containing minimal synthetic media supplemented with 50 μM D-erythro-sphingosine  
20 (Sigma Chemical Co., St. Louis, MO) and 0.0015% NP40 (Sigma Chemical Co.). At this concentration of NP40, no effects on cell viability were observed. Plates were incubated at 30°C for two days and assessed visually for differences in growth. Transformants containing the mouse SPL gene were resistant to sphingosine present in galactose-containing plates (Figure 5). A strain  
25 transformed with vector alone remained sensitive to sphingosine. Therefore, the mouse SPL gene was capable of reversing the sphingosine-sensitive phenotype of a yeast *bst1Δ* strain.

In order to determine whether the mouse SPL gene was able to restore biochemical SPL activity to the *bst1Δ* strain, the untransformed *bst1Δ*  
30 strain, and the *bst1Δ* strain transformed with pYES2 containing either *BST1* or the

putative mouse SPL gene were grown to exponential phase ( $A_{600}=1.0$ ) in either minimal (JS16) or uracil medium containing galactose as a carbon source. Whole cell extracts were prepared from each strain as described above, adjusted for protein concentration, and evaluated for sphingosine phosphate lyase activity as described above, using  $^3\text{H}$ -dihydrosphingosine-1-phosphate (American Radiolabeled Chemicals, Inc., St. Louis, MO). Qualitative analysis of product was performed by autoradiography. Quantitative measurement was performed by scraping TLC plates and determining radioactivity present using a standard scintillation counter.

10           The results of the sphingosine phosphate lyase assays are shown in Figures 6A and 6B. Expression of both the yeast and mouse sequences restored SPL activity to the *bst1* $\Delta$  strain, whereas vector alone had no effect, confirming the identity of the mouse sequence as SPL.

To determine whether the expression of the mouse SPL transcript coincided with previously reported tissue-specific SPL activity in the mouse, total RNA was obtained from a variety of mouse tissues and probed with the complete mouse SPL cDNA sequence. Northern analysis was performed as described by Thomas, *Proc. Natl. Acad. Sci. USA* 77:5201, 1980, using a full length mouse SPL cDNA probe labeled by random labeling technique (Cobianchi and Wilson, 15           *Meth. Enzymol.* 152:94-110, 1987). This analysis revealed a pattern of expression consistent with the known SPL activity in various mouse tissues, providing 20           further confirmation that this sequence encodes mouse SPL (Figure 7).

### Example 3

#### 25           Isolation and Characterization of Human SPL cDNA

This Example illustrates the identification of an endogenous human cDNA.

An EST database was searched using the mouse SPL sequence described herein. Two distinct EST sequences having strong homology to the mouse sequence were identified from human sources. One of these sequences 30           corresponded to the C-terminus, and the other corresponded to the N-terminus.

Primers were designed based on these sequences, and a DNA fragment was amplified by PCR from a human expression library made from human glioblastoma multiforme tissue RNA. The fragment was sequenced and was shown to contain a deletion, so the primers were used to amplify the gene from  
5 human fibroblast RNA. This gene has the sequence provided in SEQ ID NO:3, and the sequence of the gene containing the deletion is provided in SEQ ID NO:9.

From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for the purpose of  
10 illustration, various modifications may be made without deviating from the spirit and scope of the invention.

Claims

1. An isolated polynucleotide comprising a sequence selected from the group consisting of:
  - (a) a sequence recited in SEQ ID NO:1;
  - (b) a sequence recited in SEQ ID NO:3;
  - (c) nucleotide sequences that hybridize to a polynucleotide complementary to either of the foregoing sequences under moderately stringent conditions, wherein the nucleotide sequences encode polypeptides having sphingosine-1-phosphate lyase activity; and
  - (d) nucleotide sequences that encode a polypeptide encoded by any of the foregoing sequences.
2. An isolated polynucleotide encoding a polypeptide recited in SEQ ID NO:2, or a variant of such a polypeptide that has sphingosine-1-phosphate lyase activity.
3. An isolated polynucleotide encoding a polypeptide comprising a sequence recited in SEQ ID NO:4, or a variant of such a polypeptide that has sphingosine-1-phosphate lyase activity.
4. A recombinant expression vector comprising a polynucleotide according to any one of claims 1-3.
5. A host cell transformed or transfected with an expression vector according to claim 4.
6. An isolated polynucleotide comprising at least 100 nucleotides complementary to a sequence recited in SEQ ID NO:1 or 3.

7. A method for preparing a sphingosine-1-phosphate lyase, the method comprising culturing a host cell transformed or transfected with a polynucleotide according to any one of claims 1-3 under conditions promoting expression of the polynucleotide and recovering a sphingosine-1-phosphate lyase.
8. A polypeptide comprising an amino acid sequence encoded by a polynucleotide according to claim 1.
9. A polypeptide comprising an amino acid sequence recited in SEQ ID NO:2 or 4, or a variant thereof, wherein the polypeptide has sphingosine-1-phosphate lyase activity.
10. A method for identifying an agent that modulates sphingosine-1-phosphate lyase activity, comprising:
- (a) contacting a candidate agent with cells that express sphingosine-1-phosphate lyase; and
  - (b) subsequently measuring the level of sphingosine-1-phosphate lyase or mRNA encoding sphingosine-1-phosphate lyase in the cells, relative to a predetermined level in the absence of candidate agent, and therefrom identifying an agent that modulates sphingosine-1-phosphate lyase activity.
11. A method for identifying an agent that modulates sphingosine-1-phosphate lyase activity, comprising:
- (a) contacting a candidate agent with a polypeptide comprising a sequence recited in any one of SEQ ID NOs: 2, 4, 6 or 8, or a variant of such a sequence having sphingosine-1-phosphate lyase activity, wherein the step of contacting is carried out under conditions and for a time sufficient to allow the candidate modulator to interact with the polypeptide; and
  - (b) subsequently measuring the ability of the polypeptide to degrade sphingosine-1-phosphate or a derivative thereof, relative to an ability in the absence



of candidate agent, and therefrom identifying an agent that modulates sphingosine-1-phosphate lyase activity.

12. A method according to claim 11, wherein the step of contacting is performed by incubating a cell expressing the polypeptide with the candidate modulator, and wherein the step of measuring the ability to degrade sphingosine-1-phosphate is performed using an *in vitro* assay and a cellular extract.

13. A pharmaceutical composition comprising an agent that modulates sphingosine-1-phosphate lyase activity in combination with a pharmaceutically acceptable carrier.

14. A composition according to claim 13, wherein the sphingosine-1-phosphate lyase comprises a sequence recited in any one of SEQ ID NOs:2, 4 or 6.

15. A composition according to claim 13, wherein the agent inhibits expression of an endogenous sphingosine-1-phosphate lyase gene.

16. A composition according to claim 15, wherein the agent comprises a polynucleotide.

17. A composition according to claim 13, wherein the agent inhibits the ability of an endogenous sphingosine-1-phosphate lyase to degrade sphingosine-1-phosphate.

18. A composition according to claim 17, wherein the agent comprises an antibody or an antigen-binding fragment thereof.

19. A method for modulating sphingosine-1-phosphate lyase activity, comprising contacting a sphingosine-1-phosphate lyase with an effective amount of an agent that modulates sphingosine-1-phosphate lyase activity, wherein the step of contacting is

performed under conditions and for a time sufficient to allow the agent and the sphingosine-1-phosphate lyase to interact.

20. A method according to claim 19, wherein the step of contacting is performed by incubating a cell expressing the polypeptide with the agent.

21. A method according to claim 19, wherein the agent inhibits expression of an endogenous sphingosine-1-phosphate lyase gene.

22. A method according to claim 21, wherein the agent comprises a polynucleotide.

23. A method according to claim 19, wherein the agent is capable of inhibiting the ability of a polypeptide comprising a sequence recited in any one of SEQ ID NOs: 2, 4 or 6 to degrade sphingosine-1-phosphate.

24. A method for inhibiting the growth of a cancer cell, comprising contacting a cancer cell with an agent that inhibits sphingosine-1-phosphate lyase activity.

25. A method according to claim 24, wherein the agent inhibits expression of an endogenous sphingosine-1-phosphate lyase gene.

26. A method according to claim 25, wherein the agent comprises a polynucleotide according to claim 6.

27. A method according to claim 24, wherein the agent is capable of inhibiting the ability of a polypeptide comprising a sequence recited in any one of SEQ ID NOs: 2, 4 or 6 to degrade sphingosine-1-phosphate.

28. A method according to claim 24, wherein the cancer cell is a breast cancer cell.

29. A method for inhibiting the development and/or metastasis of a cancer in a mammal, comprising administering to a mammal an agent that inhibits sphingosine-1-phosphate lyase activity.

30. A method according to claim 29, wherein the agent inhibits expression of an endogenous sphingosine-1-phosphate lyase gene.

31. A method according to claim 30, wherein the agent comprises a polynucleotide according to claim 6.

32. A method according to claim 29, wherein the agent is capable of inhibiting the ability of a polypeptide comprising a sequence recited in any one of SEQ ID NOs: 2, 4 or 6 to degrade sphingosine-1-phosphate.

33. A method according to claim 29, wherein the agent is linked to a targeting component.

34. A method according to claim 33, wherein the targeting component is an anti-tumor antibody.

35. A method according to claim 33, wherein the targeting component binds to an estrogen receptor.

36. A method according to claim 29, wherein the mammal is afflicted with breast cancer.

37. A method for diagnosing a cancer in a mammal, comprising detecting an alteration in an endogenous sphingosine-1-phosphate lyase gene in a sample obtained from a mammal, and therefrom diagnosing a cancer in the mammal.

38. A method according to claim 37, wherein the alteration is a deletion.
39. A method according to claim 37, wherein the cancer is breast cancer and the sample is a breast tumor biopsy.
40. A method for evaluating a cancer prognosis, comprising determining the presence or absence of an alteration in an endogenous sphingosine-1-phosphate lyase gene in a sample obtained from a mammal afflicted with cancer, and therefrom determining a prognosis.
41. A method according to claim 40, wherein the alteration is a deletion.
42. A method according to claim 41, wherein the deletion comprises amino acid residues 354-433 of SEQ ID NO:4.
43. A method according to claim 40, wherein the cancer is breast cancer and the sample is a breast tumor biopsy.
44. An isolated antibody that binds to a polypeptide having a sequence recited in any one of SEQ ID NOs: 2, 4 or 6.
45. A monoclonal antibody that binds to a polypeptide having a sequence recited in any one of SEQ ID NOs: 2, 4 or 6.
46. An antibody according to claim 44 or claim 45, wherein the antibody inhibits the ability of a polypeptide having a sequence recited in any one of SEQ ID NOs: 2, 4 or 6 to degrade sphingosine-1-phosphate.
47. A method for detecting sphingosine-1-phosphate lyase in a sample, comprising:

(a) contacting a sample with an antibody according to claim 44 or claim 45 under conditions and for a time sufficient to allow the antibody to bind to sphingosine-1-phosphate lyase; and

(b) detecting in the sample the presence of sphingosine-1-phosphate lyase bound to the antibody.

48. A kit for detecting sphingosine-1-phosphate lyase in a sample, comprising an antibody according to claim 44 or claim 45 and a buffer or detection reagent.

49. A kit for detecting an alteration in a sphingosine-1-phosphate gene in a sample, comprising a polynucleotide according to claim 6 and a detection reagent.

50. A transgenic animal in which sphingosine-1-phosphate lyase activity is reduced compared to a wild-type animal.

51. A cell line derived from a transgenic animal according to claim 50.

1/20

*Fig. 1A*

ATG AGT GGA GTA TCA AAT AAA ACA GTA TCA ATT AAT GGT TGG TAT GGC	48
Met Ser Gly Val Ser Asn Lys Thr Val Ser Ile Asn Gly Trp Tyr Gly	
1 5 10 15	
ATG CCA ATT CAT TTA CTA AGG GAA GAA GGC GAC TTT GCC CAG TTT ATG	96
Met Pro Ile His Leu Leu Arg Glu Glu Gly Asp Phe Ala Gln Phe Met	
20 25 30	
ATT CTA ACC ATC AAC GAA TTA AAA ATA GCC ATA CAT GGT TAC CTC AGA	144
Ile Leu Thr Ile Asn Glu Leu Lys Ile Ala Ile His Gly Tyr Leu Arg	
35 40 45	
AAT ACC CCA TGG TAC AAC ATG TTG AAG GAT TAT TTG TTT GTG ATC TTT	192
Asn Thr Pro Trp Tyr Asn Met Leu Lys Asp Tyr Leu Phe Val Ile Phe	
50 55 60	
TGT TAC AAG CTA ATA AGT AAT TTT TTT TAT CTG TTG AAA GTT TAT GGG	240
Cys Tyr Lys Leu Ile Ser Asn Phe Phe Tyr Leu Leu Lys Val Tyr Gly	
65 70 75 80	
CCG GTG AGG TTA GCA GTG AGA ACA TAC GAG CAT AGT TCC AGA AGA TTG	288
Pro Val Arg Leu Ala Val Arg Thr Tyr Glu His Ser Ser Arg Arg Leu	
85 90 95	
TTT CGT TGG TTA TTG GAC TCA CCA TTT TTG AGG GGT ACC GTA GAA AAG	336
Phe Arg Trp Leu Leu Asp Ser Pro Phe Leu Arg Gly Thr Val Glu Lys	
100 105 110	
GAA GTC ACA AAG GTC AAA CAA TCG ATC GAA GAC GAA CTA ATT AGA TCG	384
Glu Val Thr Lys Val Lys Gln Ser Ile Glu Asp Glu Leu Ile Arg Ser	
115 120 125	
GAC TCT CAG TTA ATG AAT TTC CCA CAG TTG CCA TCC AAT GGG ATA CCT	432
Asp Ser Gln Leu Met Asn Phe Pro Gln Leu Pro Ser Asn Gly Ile Pro	
130 135 140	
CAG GAT GAT GTT ATT GAA GAG CTA AAT AAA TTG AAC GAC TTG ATA CCA	480
Gln Asp Asp Val Ile Glu Glu Leu Asn Lys Leu Asn Asp Leu Ile Pro	
145 150 155 160	
CAT ACC CAA TGG AAG GAA GGA AAG GTC TCT GGT GCC GTT TAC CAC GGT	528
His Thr Gln Trp Lys Glu Gly Lys Val Ser Gly Ala Val Tyr His Gly	
165 170 175	

2/20

*Fig. 1B*

GGT GAT GAT TTG ATC CAC TTA CAA ACA ATC GCA TAC GAA AAA TAT TGC	576
Gly Asp Asp Leu Ile His Leu Gln Thr Ile Ala Tyr Glu Lys Tyr Cys	
180 185 190	
GTT GCC AAT CAA TTA CAT CCC GAT GTC TTT CCT GCC GTA CGT AAA ATG	624
Val Ala Asn Gln Leu His Pro Asp Val Phe Pro Ala Val Arg Lys Met	
195 200 205	
GAA TCC GAA GTG GTT TCT ATG GTT TTA AGA ATG TTT AAT GCC CCT TCT	672
Glu Ser Glu Val Val Ser Met Val Leu Arg Met Phe Asn Ala Pro Ser	
210 215 220	
GAT ACA GGT TGT GGT ACC ACA ACT TCA GGT GGT ACA GAA TCC TTG CTT	720
Asp Thr Gly Cys Gly Thr Thr Thr Ser Gly Gly Thr Glu Ser Leu Leu	
225 230 235 240	
TTA GCA TGT CTG AGC GCT AAA ATG TAT GCC CTT CAT CAT CGT GGA ATC	768
Leu Ala Cys Leu Ser Ala Lys Met Tyr Ala Leu His His Arg Gly Ile	
245 250 255	
ACC GAA CCA GAA ATA ATT GCT CCC GTA ACT GCA CAT GCT GGG TTT GAC	816
Thr Glu Pro Glu Ile Ile Ala Pro Val Thr Ala His Ala Gly Phe Asp	
260 265 270	
AAA GCT GCT TAT TAC TTT GGC ATG AAG CTA CGC CAC GTG GAG CTA GAT	864
Lys Ala Ala Tyr Tyr Phe Gly Met Lys Leu Arg His Val Glu Leu Asp	
275 280 285	
CCA ACG ACA TAT CAA GTG GAC CTG GGA AAA GTG AAA AAA TTC ATC AAT	912
Pro Thr Thr Tyr Gln Val Asp Leu Gly Lys Val Lys Lys Phe Ile Asn	
290 295 300	
AAG AAC ACA ATT TTA CTG GTC GGT TCC GCT CCA AAC TTT CCT CAT GGT	960
Lys Asn Thr Ile Leu Leu Val Gly Ser Ala Pro Asn Phe Pro His Gly	
305 310 315 320	
ATT GCC GAT GAT ATT GAA GGA TTG GGT AAA ATA GCA CAA AAA TAT AAA	1008
Ile Ala Asp Asp Ile Glu Gly Leu Gly Lys Ile Ala Gln Lys Tyr Lys	
325 330 335	
CTT CCT TTA CAC GTC GAC AGT TGT CTA GGT TCC TTT ATT GTT TCA TTT	1056
Leu Pro Leu His Val Asp Ser Cys Leu Gly Ser Phe Ile Val Ser Phe	
340 345 350	

3/20

*Fig. 1C*

ATG GAA AAG GCT GGT TAC AAA AAT CTG CCA TTA CTT GAC TTT AGA GTC Met Glu Lys Ala Gly Tyr Lys Asn Leu Pro Leu Leu Asp Phe Arg Val	1104
355 360 365	
CCG GGA GTC ACC TCA ATA TCA TGT GAC ACT CAT AAA TAT GGA TTT GCA Pro Gly Val Thr Ser Ile Ser Cys Asp Thr His Lys Tyr Gly Phe Ala	1152
370 375 380	
CCA AAA GGC TCG TCA GTT ATA ATG TAT AGA AAC AGC GAC TTA CGA ATG Pro Lys Gly Ser Ser Val Ile Met Tyr Arg Asn Ser Asp Leu Arg Met	1200
385 390 395 400	
CAT CAG TAT TAC GTA AAT CCT GCT TGG ACT GGC GGG TTA TAT GGC TCT His Gln Tyr Tyr Val Asn Pro Ala Trp Thr Gly Gly Leu Tyr Gly Ser	1248
405 410 415	
CCT ACA TTA GCA GGG TCC AGG CCT GGT GCT ATT GTC GTA GGT TGT TGG Pro Thr Leu Ala Gly Ser Arg Pro Gly Ala Ile Val Val Gly Cys Trp	1296
420 425 430	
GCC ACT ATG GTC AAC ATG GGT GAA AAT GGG TAC ATT GAG TCG TGC CAA Ala Thr Met Val Asn Met Gly Glu Asn Gly Tyr Ile Glu Ser Cys Gln	1344
435 440 445	
GAA ATA GTC GGT GCA GCA ATG AAG TTT AAA AAA TAC ATC CAG GAA AAC Glu Ile Val Gly Ala Ala Met Lys Phe Lys Lys Tyr Ile Gln Glu Asn	1392
450 455 460	
ATT CCA GAC CTG AAT ATA ATG GGC AAC CCT AGA TAT TCA GTC ATT TCA Ile Pro Asp Leu Asn Ile Met Gly Asn Pro Arg Tyr Ser Val Ile Ser	1440
465 470 475 480	
TTT TCT TCA AAG ACC TTG AAC ATA CAC GAA CTA TCT GAC AGG TTG TCC Phe Ser Ser Lys Thr Leu Asn Ile His Glu Leu Ser Asp Arg Leu Ser	1488
485 490 495	
AAG AAA GGC TGG CAT TTC AAT GCC CTA CAA AAG CCG GTT GCA CTA CAC Lys Lys Gly Trp His Phe Asn Ala Leu Gln Lys Pro Val Ala Leu His	1536
500 505 510	
ATG GCC TTC ACG AGA TTG AGC GCT CAT GTT GTG GAT GAG ATC TGC GAC Met Ala Phe Thr Arg Leu Ser Ala His Val Val Asp Glu Ile Cys Asp	1584
515 520 525	



4/20

*Fig. 1D*

ATT TTA CGT ACT ACC GTG CAA GAG TTG AAG AGC GAA TCA AAT TCT AAA	1632
Ile Leu Arg Thr Thr Val Gln Glu Leu Lys Ser Glu Ser Asn Ser Lys	
530 535 540	
CCA TCC CCA GAC GGA ACT AGC GCT CTA TAT GGT GTC GCC GGG AGC GTT	1680
Pro Ser Pro Asp Gly Thr Ser Ala Leu Tyr Gly Val Ala Gly Ser Val	
545 550 555 560	
AAA ACT GCT GGC GTT GCA GAC AAA TTG ATT GTG GGA TTC CTA GAC GCA	1728
Lys Thr Ala Gly Val Ala Asp Lys Leu Ile Val Gly Phe Leu Asp Ala	
565 570 575	
TTA TAC AAG TTG GGT CCA GGA GAG GAT ACC GCC ACC AAG TAG	1770
Leu Tyr Lys Leu Gly Pro Gly Glu Asp Thr Ala Thr Lys	
580 585	

5/20

*Fig. 2A*

C. elegans S-1-P Lyase Gene [1 to 1629] -&gt; 1-phase Translation

DNA sequence 1629 b.p. ATGGATTTTGCA ... TTAACAGAGTGA linear

```

1/1                               31/11
ATG GAT TTT GCA CTG GAG CAA TAT CAT AGT GCA AAG GAT TTG TTA ATA TTT GAG CTT CGA
M D F A L E Q Y H S A K D L L I F E L R
61/21                             91/31
AAG TTC AAT CCA ATT GTT CTG GTT TCT AGT ACT ATT GTT GCA ACA TAC GTA CTC ACC AAT
K F N P I V L V S S T I V A T Y V L T N
121/41                           151/51
CTG AGA CAT ATG CAT TTA GAT GAA ATG GGC ATC CGG AAA CGT TTG AGC ACT TGG TTT TTC
L R H M H L D E M G I R K R L S T W F F
181/61                           211/71
ACC ACT GTA AAG CGT GTG CCT TTC ATC AGG AAA ATG ATT GAC AAA CAA CTA AAC GAA GTA
T T V K R V P F I R K M I D K Q L N E V
241/81                           271/91
AAG GAC GAG CTT GAG AAA AGT CTG AGA ATT GTG GAT CGA AGC ACC GAA TAC TTC ACT ACA
K D E L E K S L R I V D R S T E Y F T T
301/101                          331/111
ATC CCA AGC CAT TCA GTT GGA AGA ACT GAA GTA CTT CGC CTT GCT GCC ATC TAT GAT GAT
I P S H S V G R T E V L R L A A I Y D D
361/121                          391/131
TTG GAA GGA CCA GCT TTT TTG GAA GGA AGA GTA TCT GGA GCA GTC TTC AAT AGA GAA GAC
L E G P A F L E G R V S G A V F N R E D
421/141                          451/151
GAC AAG GAC GAA CGG GAG ATG TAT GAG GAG GTG TTC GGA AAA TTT GCC TGG ACC AAC CCA
D K D E R E M Y E E V F G K F A W T N P
481/161                          511/171
CTT TGG CCA AAA TTG TTC CCT GGA GTG AGA ATC ATG GAG GCT GAA GTT GTT CGC ATG TGT
L W P K L F P G V R I M E A E V V R M C
541/181                          571/191
TGT AAT ATG ATG AAT GGA GAT TCG GAG ACA TGT GGA ACT ATG TCA ACT GGT GGA TCC ATT
C N M M N G D S E T C G T M S T G G S I
601/201                          631/211
TCA ATT CTT TTG GCG TGC CTG GCT CAT CGT AAT CGT CTT TTG AAA AGA GGA GAA AAG TAC
S I L L A C L A H R N R L L K R G E K Y
661/221                          691/231
ACA GAG ATG ATT GTC CCA TCA TCC GTC CAT GCA GCG TTC TTC AAA GCT GCC GAA TGT TTC
T E M I V P S S V H A A F F K A A E C F

```

6/20

*Fig. 2B*

C. elegans S-1-P Lyase Gene [1 to 1629] -&gt; 1-phase Translation

```

721/241                               751/251
CGT ATC AAA GTT CGC AAG ATT CCA GTT GAT CCT GTT ACT TTC AAA GTA GAC CTT GTC AAA
R I K V R K I P V D P V T F K V D L V K
781/261                               811/271
ATG AAA GCC GCA ATT AAC AAG AGA ACA TGT ATG TTA GTT GGA TCT GCT CCA AAC TTT CCA
M K A A I N K R T C M L V G S A P N F P
841/281                               871/291
TTT GGA ACT GTT GAT GAC ATT GAA GCT ATT GGA CAG CTA GGA CTT GAA TAT GAC ATC CCA
F G T V D D I E A I G Q L G L E Y D I P
901/301                               931/311
GTT CAT GTT GAT GCT TGT CTT GGT GGT TTC CTT CTT CCA TTC CTT GAA GAA GAC GAG ATT
V H V D A C L G G F L L P F L E E D E I
961/321                               991/331
CGC TAT GAC TTC CGT GTT CCT GGT GTA TCT TCG ATT TCT GCA GAT AGT CAC AAA TAC GGA
R Y D F R V P G V S S I S A D S H K Y G
1021/341                             1051/351
CTC GCT CCA AAG GGG TCA TCA GTT GTT CTT TAT CGC AAT AAG GAA CTT CTT CAT AAT CAG
L A P K G S S V V L Y R N K E L L H N Q
1081/361                             1111/371
TAC TTC TGT GAT GCT GAT TGG CAA GGA GGT ATC TAT GCA TCG GCT ACT ATG GAA GGA TCA
Y F C D A D W Q G G I Y A S A T M E G S
1141/381                             1171/391
CGC GCT GGG CAC AAC ATT GCA CTT TGC TGG GCC GCA ATG CTT TAT CAC GCT CAG GAA GGA
R A G H N I A L C W A A M L Y H A Q E G
1201/401                             1231/411
TAC AAG GCC AAT GCT AGA AAG ATT GTT GAC ACT ACA AGA AAG ATT AGA AAT GGA CTT TCA
Y K A N A R K I V D T T R K I R N G L S
1261/421                             1291/431
AAC ATT AAG GGA ATC AAA TTA CAA GGG CCA AGT GAT GTT TGT ATT GTT AGC TGG ACA ACC
N I K G I K L Q G P S D V C I V S W T T
1321/441                             1351/451
AAT GAT GGA GTT GAA CTC TAC AGA TTC CAT AAC TTC ATG AAG GAA AAA CAT TGG CAA CTG
N D G V E L Y R F H N F M K E K H W Q L
1381/461                             1411/471
AAT GGA CTT CAA TTC CCA GCT GGA GTT CAT ATC ATG GTC ACT ATG AAT CAT ACT CAT CCT
N G L Q F P A G V H I M V T M N H T H P
1441/481                             1471/491
GGA CTC GCT GAA GCT TTC GTC GCC GAT TGC AGA GCT GCA GTT GAG TTT GTC AAA AGC CAC
G L A E A F V A D C R A A V E F V K S H

```

7/20

*Fig. 2C*

*C. elegans* S-1-P Lyase Gene [1 to 1629] -> 1-phase Translation

```
1501/501      1531/511
AAA CCA TCG GAA TCC GAC AAG ACA AGT GAA GCA GCC ATC TAC GGA CTT GCT CAA AGT ATT
K  P S E S D K T S E A A I Y G L A Q S I
1561/521      1591/531
CCA GAC CGA TCG CTT GTT CAC GAG TTT GCT CAC AGC TAT ATC GAT GCT GTT TAT GCT TTA
P  D R S L V H E F A H S Y I D A V Y A L
1621/541
ACA GAG TGA
T  E  *
```

8/20

*Fig. 3A*

Mouse S-1-P Lyase Gene -&gt; 1-phase Translation

DNA sequence 1707 b.p. ATGCCCCGAACC ... AAGCCCCGCTGA linear

```

1/1                               31/11
ATG CCC GGA ACC GAC CTC CTC AAG CTG AAG GAC TTC GAG CCT TAT TTG GAG ATT TTG GAA
M  P  G  T  D  L  L  K  L  K  D  F  E  P  Y  L  I  L  E  S
61/21                             91/31
TCT TAT TCC ACA AAA GCC AAG AAT TAT GTG AAT GGA TAT TGC ACC AAA TAT GAG CCC TGG
E  Y  S  T  K  A  K  N  Y  V  N  G  Y  C  T  K  Y  E  P  W
121/41                           151/51
CAG CTC ATT GCG TGG AGT GTC CTG TGT ACT CTG CTG ATA GTC TGG GTG TAT GAG CTT ATC
Q  L  I  A  W  S  V  L  C  T  L  L  I  V  W  V  Y  E  L  I
181/61                           211/71
TTC CAG CCA GAG AGT TTA TGG TCT CGG TTT AAA AAA AAA TTA TTT AAG CTT ATC AGG AAG
F  Q  P  E  S  L  W  S  R  F  K  K  K  L  F  K  L  I  R  K
241/81                           271/91
ATG CCA TTT ATT GGA CGT AAG ATC GAA CAA CAG GTG AGC AAA GCC AAG AAG GAT CTT GTC
M  P  F  I  G  R  K  I  E  Q  Q  V  S  K  A  K  K  D  L  V
301/101                          331/111
AAG AAC ATG CCA TTC CTA AAG GTG GAC AAG GAT TAT GTG AAA ACT CTG CCT GCT CAG GGT
K  N  M  P  F  L  K  V  D  K  D  Y  V  K  T  L  P  A  Q  G
361/121                         391/131
ATG GGC ACA GCT GAG GTT CTG GAG AGA CTC AAG GAG TAC AGC TCC ATG GAT GGT TCC TGG
M  G  T  A  E  V  L  E  R  L  K  E  Y  S  S  M  D  G  S  W
421/141                         451/151
CAA GAA GGG AAA GCC TCA GGA GCT GTG TAC AAT GGG GAA CCG AAG CTC ACG GAG CTG CTG
Q  E  G  K  A  S  G  A  V  Y  N  G  E  P  K  L  T  E  L  L
481/161                         511/171
GTG CAG GCT TAT GGA GAA TTC ACG TGG AGC AAT CCA CTG CAT CCA GAT ATC TTC CCT GGA
V  Q  A  Y  G  E  F  T  W  S  N  P  L  H  P  D  I  F  P  G
541/181                         571/191
TTG CGG AAG TTA GAG GCA GAA ATC GTT AGG ATG ACT TGT TCC CTC TTC AAT GGG GGA CCA
L  R  K  L  E  A  E  I  V  R  M  T  C  S  L  F  N  G  G  P
601/201                         631/211
GAT TCC TGT GGA TGT GTG ACT TCT GGG GGA ACG GAA AGC ATC CTG ATG GCC TGC AAA GCT
D  S  C  G  C  V  T  S  G  G  T  E  S  I  L  M  A  C  K  A
661/221                         691/231
TAC CGG GAC TTG GCG TTA GAG AAG GGG ATC AAA ACT CCA GAA ATT GTG GCT CCC GAG AGT
Y  R  D  L  A  L  E  K  G  I  K  T  P  E  I  V  A  P  E  S
721/241                         751/251
GCC CAT GCT GCA TTC GAC AAA GCA GCT CAT TAT TTT GGG ATG AAG ATT GTC CGA GTT GCA
A  H  A  A  F  D  K  A  A  H  Y  F  G  M  K  I  V  R  V  A

```

9/20

*Fig. 3B*

Mouse S-1-P Lyase Gene -&gt; 1-phase Translation

781/261 811/271  
 CTG AAA AAG AAC ATG GAG GTG GAT GTG CAG GCA ATG AAG AGA GCC ATC TCC AGG AAC ACA  
 L K K N M E V D V Q A M K R A I S R N T  
 841/281 871/291  
 GCT ATG CTG GTC TGT TCT ACC CCA CAG TTT CCT CAT GGT GTG ATG GAT CCT GTC CCC GAA  
 A M L V C S T P Q F P H G V M D P V P E  
 901/301 931/311  
 GTG GCC AAG TTA ACT GTC AGA TAT AAA ATC CCA CTC CAT GTG GAT GCT TGT CTG GGG GGC  
 V A K L T V R Y K I P L H V D A C L G G  
 961/321 991/331  
 TTC CTC ATT GTC TTC ATG GAG AAA GCA GGG TAC CCA CTG GAG AAA CCA TTT GAT TTC CGG  
 F L I V F M E K A G Y P L E K P F D F R  
 1021/341 1051/351  
 GTG AAA GGT GTG ACC AGC ATT TCA GCA GAT ACT CAT AAG TAT GGC TAT GCT CCT AAA GGT  
 V K G V T S I S A D T H K Y G Y A P K G  
 1081/361 1111/371  
 TCA TCA GTG GTG ATG TAC TCT AAC GAG AAG TAC AGG ACG TAC CAG TTC TTT GTT GGT GCA  
 S S V V M Y S N E K Y R T Y Q F F V G A  
 1141/381 1171/391  
 GAC TGG CAA GGT GGT GTC TAC GCA TCT CCA AGC ATA GCT GGC TCA CGG CCT GGT GGC ATC  
 D W Q G G V Y A S P S I A G S R P G G I  
 1201/401 1231/411  
 ATT GCA GCC TGT TGG GCG GCC TTG ATG CAC TTC GGT GAG AAC GGC TAT GTT GAA GCT ACC  
 I A A C W A A L M H F G E N G Y V E A T  
 1261/421 1291/431  
 AAA CAG ATC ATC AAA ACT GCT CGC TTC CTG AAG TCA GAA CTG GAA AAC ATC AAA AAC ATC  
 K Q I I K T A R F L K S E L E N I K N I  
 1321/441 1351/451  
 TTC ATT TTC GGT GAT CCT CAA TTG TCA GTT ATT GCT CTG GGA TCC AAC GAT TTT GAC ATT  
 F I F G D P Q L S V I A L G S N D F D I  
 1381/461 1411/471  
 TAC CGA CTA TCT AAT ATG ATG TCT GCT AAG GGG TGG AAT TTT AAC TAC CTG CAG TTC CCA  
 Y R L S N M M S A K G W N F N Y L Q F P  
 1441/481 1471/491  
 AGA AGC ATT CAT TTC TGC ATT ACG TTA GTA CAT ACT CGG AAG CGA GTG GCG ATC CAG TTC  
 R S I H F C I T L V H T R K R V A I Q F  
 1501/501 1531/511  
 CTA AAG GAT ATC CGG GAA TCA GTC ACA CAA ATC ATG AAG AAT CCT AAA GCT AAG ACC ACA  
 L K D I R E S V T Q I M K N P K A K T T

10/20

*Fig. 3C*

Mouse S-1-P Lyase Gene -&gt; 1-phase Translation

1561/521	1591/531
GGA ATG GGT GCC ATC TAT GGC ATG GCC CAG GCA ACC ATT GAC AGG AAG CTG GTT GCA GAA	
G M G A I Y G M A Q A T I D R K L V A E	
1621/541	1651/551
ATA TCC TCC GTC TTC TTG GAC TGC CTT TAT ACT ACG GAC CCC GTG ACT CAG GGC AAC CAG	
I S S V F L D C L Y T T D P V T Q G N Q	
1681/561	
ATG AAC GGT TCT CCA AAG CCC CGC TGA	
M N G S P K P R *	

11/20

*Fig. 4A*

CLUSTAL W(1.60) multiple sequence alignment: C.elegans/Yeast/Mouse Lyase Seq.

```

C.elgns -----MDFALEQYHS-AKDLLIFELRKFNPIVLVS
Yeast   MSGVSNKTVSINGWYGMPIHLLREEGDAQFMILTINELKIAIHGYLRNTPWYNMLKDYL
Mouse   -----MPGTDLLKLKDFEPYLEILESYSYTKAKNYVNGYCTKYEPWQLIA
               *

C.elgns STIVATYVLTNLRHMLDE-----MGIRKRLSTWFFTTVKRVPFIRKMIDKQLNEVKDE
Yeast   FVIFCYKLISNFFYLLKVYGPVRLAVRTYEHSSRRLFRWLLDSPFLRGTVKEVTKVKQS
Mouse   WSVLCTLLIVWYELIFQP-----ESLSRFKKLFLIRKMPFIGRKIEQQVSKAKKD
               *   **   ..... *

C.elgns LEKSLRIVDRSTEYFTTIPSHSVGRTEVLRLLAAIYDDLEGP-AFLEGRVSGAVFNREDDK
Yeast   IEDELIRSDSQLMNFQPLPSNGIPQDDVIEELNKLNDLIPHTQWKEGVSGAVYHGG--D
Mouse   LVKNMPFLKVDKDYVKTLPQGMGTAEVLERLKEYSSMDG--SWQEGKASGAVYNGE--P
               *   *   *   **   ****

C.elgns DEREMYEEVFGKFAWTNPLWPKLPGVRIMEAEVVRMCCNMNGDSET-CGTMSTGGSIS
Yeast   DLIHQLTIAYEKYCVANQLHPDVFPVRKMESEVSMVLRMFNAPSDTGCGTTTSGGTES
Mouse   KLTLLVQAYGEFTWSNPLHPDIFPGLRKLEAEIVRMTCSLFNGGPDS-CGCVTSGGTES
               * * * * * * * * * * * * * * * * * * * * * *

C.elgns ILLACLARNRLK-RGEKYTEMIVPSSVHAFFKAAECFRKVRKIPVDPVTFKVDLVK
Yeast   LLLACLAKMYALHHRGITEPEIIAPVTAHAGFDKAAHYFGMKLRHVELDPTTYQVDLCK
Mouse   ILMACKAYROLALE-KGKTPEIVAPESAHAADFKAHYFGMKIVRVALK-KNMEVDVQA
               * * * * * * * * * * * * * * * * * * * * * *

C.elgns MKAANKRKTCLVGSAPNFPFGTVDDIEATGQLGLEYOIPVHVDACLGGFLLPFLEED--
Yeast   VKKFINKNTILLVGSAPNFPHGIADDIEGLGKIAQKYKLPVHVDCLGSFIVSFMKAGY
Mouse   MKRAISRNTAMLCSTPQFPHGVMDPVPEVAKLTVRYKIPLHVDACLGGFLIVFMKAGY
               * * * * * * * * * * * * * * * * * * * * * *

C.elgns --EIRYDFRVPGVSSISADSHKYGLAPKGSSVLYRNKELLHNQYFCADWQGGIYASAT
Yeast   KNLPLDFRVPGVTSISCDTHKYGFAPKGSSVIMYRNSDLRMHQYVYNPAWTGGLYGSPT
Mouse   PLEKPFDFRVKGVTSISADTHKYGYAPKGSSVMYSNEKYRTYQFFVGADWQGGVYASPS
               **** * * * * * * * * * * * * * * * * * * * * * *

C.elgns MEGSRAGHNIALCWAAML YHAQEGYKANARKIVDTTRKIRN-GLSNIKGKLOGPSDVCI
Yeast   LAGSRPGAIVVGCWATMVMNGENGYIESCOEIVGAAMFKKYIQENIPDLNIMGNPRYSV
Mouse   IAGSRPGGI AACAALMHFGENGYVEATKQIKTARFLKS-ELENIKNIFIGDPQLSV
               *** * * * * * * * * * * * * * * * * * * * *

```



12/20

*Fig. 4B*


C.elgns	VSWTTNDGVELYRFHFMKEKHQNLQFPAGVHIMVTMNHG-LAEAFVADCRAAVE
Yeast	ISFSSKT-LNIHELSDRLSKKGWTFNALQKPVALHMAFTRLAHV--VDEICDILRTTVQ
Mouse	IALGSND-FDIYRLSNMMSAKGMFNFLQFPRSIHFCITLVHTRKRVAIQFLKDIRESVT
	.. . . . * * * * * * * .. * *

C.elgns	FKSHKPSSEDKTSEAAIYGQAQSIQDRSLVHEFAHSYIDAVYALTE-----
Yeast	ELKSESNKSPDGTSAIYGVAGSVKTAGVADKLIVGFLDALYKLGPGEDATK-----
Mouse	QIMKN-P-KAKTTGMGAIYGMQAQATIDRKLVAEISSVFLDCLYTTDPVTQGNQMNGSPKP
	. * * * . . . . * * *


C.elgns	-
Yeast	-
Mouse	R

Note to the sequence alignment: \* = identical residues; . = conserved residues; - = gap

13/20


*Fig. 5*

14/20




*Fig. 6A*

15/20

*Fig. 6B*

16/20

*Fig. 7*

17/20

*Fig. 8A*

ATG CCT AGC ACA GAC CTT CTG ATG TTG AAG GCC TTT GAG CCC TAC TTA	48
Met Pro Ser Thr Asp Leu Leu Met Leu Lys Ala Phe Glu Pro Tyr Leu	
1 5 10 15	
GAG ATT TTG GAA GTA TAC TCC ACA AAA GCC AAG AAT TAT GTA AAT GGA	96
Glu Ile Leu Glu Val Tyr Ser Thr Lys Ala Lys Asn Tyr Val Asn Gly	
20 25 30	
CAT TGC ACC AAG TAT GAG CCC TGG CAG CTA ATT GCA TGG AGT GTC GTG	144
His Cys Thr Lys Tyr Glu Pro Trp Gln Leu Ile Ala Trp Ser Val Val	
35 40 45	
TGG ACC CTG CTG ATA GTC TGG GGA TAT GAG TTT GTC TTC CAG CCA GAG	192
Trp Thr Leu Leu Ile Val Trp Gly Tyr Glu Phe Val Phe Gln Pro Glu	
50 55 60	
AGT TTA TGG TCA AGG TTT AAA AAG AAA TGT TTT AAG CTC ACC AGG AAG	240
Ser Leu Trp Ser Arg Phe Lys Lys Lys Cys Phe Lys Leu Thr Arg Lys	
65 70 75 80	
ATG CCC ATT ATT GGT CGT AAG ATT CAA GAC AAG TTG AAC AAG ACC AAG	288
Met Pro Ile Ile Gly Arg Lys Ile Gln Asp Lys Leu Asn Lys Thr Lys	
85 90 95	
GAT GAT ATT AGC AAG AAC ATG TCA TTC CTG AAA GTG GAC AAA GAG TAT	336
Asp Asp Ile Ser Lys Asn Met Ser Phe Leu Lys Val Asp Lys Glu Tyr	
100 105 110	
GTG AAA GCT TTA CCC TCC CAG GGT CTG AGC TCA TCT GCT GTT TTG GAG	384
Val Lys Ala Leu Pro Ser Gln Gly Leu Ser Ser Ser Ala Val Leu Glu	
115 120 125	
AAA CTT AAG GAG TAC AGC TCT ATG GAC GCC TTC TGG CAA GAG GGG AGA	432
Lys Leu Lys Glu Tyr Ser Ser Met Asp Ala Phe Trp Gln Glu Gly Arg	
130 135 140	
GCC TCT GGA ACA GTG TAC AGT GGG GAG GAG AAG CTC ACT GAG CTC CTT	480
Ala Ser Gly Thr Val Tyr Ser Gly Glu Glu Lys Leu Thr Glu Leu Leu	
145 150 155 160	

18/20

*Fig. 8B*

GTG AAG GCT TAT GGA GAT TTT GCA TGG AGT AAC CCC CTG CAT CCA GAT	528
Val Lys Ala Tyr Gly Asp Phe Ala Trp Ser Asn Pro Leu His Pro Asp	
165 170 175	
ATC TTC CCA GGA CTA CGC AAG ATA GAG GCA GAA ATT GTG AGG ATA GCT	576
Ile Phe Pro Gly Leu Arg Lys Ile Glu Ala Glu Ile Val Arg Ile Ala	
180 185 190	
TGT TCC CTG TTC AAT GGG GGA CCA GAT TCG TGT GGA TGT GTG ACT TCT	624
Cys Ser Leu Phe Asn Gly Gly Pro Asp Ser Cys Gly Cys Val Thr Ser	
195 200 205	
GGG GGA ACA GAA AGC ATA CTC ATG GCC TGC AAA GCA TGT CGG GAT CTG	672
Gly Gly Thr Glu Ser Ile Leu Met Ala Cys Lys Ala Cys Arg Asp Leu	
210 215 220	
GCC TTT GAG AAG GGG ATC AAA ACT CCA GAA ATT GTG GCT CCC CAA AGT	720
Ala Phe Glu Lys Gly Ile Lys Thr Pro Glu Ile Val Ala Pro Gln Ser	
225 230 235 240	
GCC CAT GCT GCA TTT AAC AAA GCA GCC AGT TAC TTT GGG ATG AAG ATT	768
Ala His Ala Ala Phe Asn Lys Ala Ala Ser Tyr Phe Gly Met Lys Ile	
245 250 255	
GTG CGG GTC CCA TTG ACG AAG ATG ATG GAG GTG GAT GTG AGG GCA ATG	816
Val Arg Val Pro Leu Thr Lys Met Met Glu Val Asp Val Arg Ala Met	
260 265 270	
AGA AGA GCT ATC TCC AGG AAC ACT GCC ATG CTC GTC TGT TCT ACC CCA	864
Arg Arg Ala Ile Ser Arg Asn Thr Ala Met Leu Val Cys Ser Thr Pro	
275 280 285	
CAG TTT CCT CAT GGT GTA ATA GAT CCT GTC CCT GAA GTG GCC AAG CTG	912
Gln Phe Pro His Gly Val Ile Asp Pro Val Pro Glu Val Ala Lys Leu	
290 295 300	
GCT GTC AAA TAC AAA ATA CCC CTT CAT GTC GAC GCT TGT CTG GGA GGC	960
Ala Val Lys Tyr Lys Ile Pro Leu His Val Asp Ala Cys Leu Gly Gly	
305 310 315 320	

19/20

*Fig. 8C*

TTC CTC ATC GTC TTT ATG GAG AAA GCA GGA TAC CCA CTG GAG CAC CCA Phe Leu Ile Val Phe Met Glu Lys Ala Gly Tyr Pro Leu Glu His Pro	1008
325 330 335	
TTT GAT TTC CGG GTG AAA GGT GTA ACC AGC ATT TCA GCT GAC ACC CAT Phe Asp Phe Arg Val Lys Gly Val Thr Ser Ile Ser Ala Asp Thr His	1056
340 345 350	
AAG TAT GGC TAT GCC CCA AAA GGC TCA TCA TTG GTG TTG TAT AGT GAC Lys Tyr Gly Tyr Ala Pro Lys Gly Ser Ser Leu Val Leu Tyr Ser Asp	1104
355 360 365	
AAG AAG TAC AGG AAC TAT CAG TTC TTC GTC GAT ACA GAT TGG CAG GGT Lys Lys Tyr Arg Asn Tyr Gln Phe Phe Val Asp Thr Asp Trp Gln Gly	1152
370 375 380	
GGC ATC TAT GCT TCC CCA ACC ATC GCA GGC TCA CGG CCT GGT GGC ATT Gly Ile Tyr Ala Ser Pro Thr Ile Ala Gly Ser Arg Pro Gly Gly Ile	1200
385 390 395 400	
AGC GCA GCC TGT TGG GCT GCC TTG ATG CAC TTC GGT GAG AAC GGC TAT Ser Ala Ala Cys Trp Ala Ala Leu Met His Phe Gly Glu Asn Gly Tyr	1248
405 410 415	
GTT GAA GCT ACC AAA CAG ATC ATC AAA ACT GCT CGC TTC CTC AAG TCA Val Glu Ala Thr Lys Gln Ile Ile Lys Thr Ala Arg Phe Leu Lys Ser	1296
420 425 430	
GAA CTG GAA AAT ATC AAA GGC ATC TTT GTT TTT GGG AAT CCC CAA TTG Glu Leu Glu Asn Ile Lys Gly Ile Phe Val Phe Gly Asn Pro Gln Leu	1344
435 440 445	
TCA CTC ATT GCT CTG GGA TCC CGT GAT TTT GAC ATC TAC CGA CTA TCA Ser Leu Ile Ala Leu Gly Ser Arg Asp Phe Asp Ile Tyr Arg Leu Ser	1392
450 455 460	
AAC CTG ATG ACT GCT AAG GGG TGG AAC TTG AAC CAG TTG CAG TTC CCA Asn Leu Met Thr Ala Lys Gly Trp Asn Leu Asn Gln Leu Gln Phe Pro	1440
465 470 475 480	



20/20

*Fig. 8D*

CCC AGT ATT CAT TTC TGC ATC ACA TTA CTA CAC GCC CGG AAA CGA GTA	1488
Pro Ser Ile His Phe Cys Ile Thr Leu Leu His Ala Arg Lys Arg Val	
485 490 495	
GCT ATA CAA TTC CTA AAG GAC ATT CGA GAA TCT GTC ACT CAA ATC ATG	1536
Ala Ile Gln Phe Leu Lys Asp Ile Arg Glu Ser Val Thr Gln Ile Met	
500 505 510	
AAG AAT CCT AAA GCG AAG ACC ACA GGA ATG GGT GCC ATC TAT GCC ATG	1584
Lys Asn Pro Lys Ala Lys Thr Thr Gly Met Gly Ala Ile Tyr Ala Met	
515 520 525	
GCC CAG ACA ACT GTT GAC AGG AAT ATG GTT GCA GAA TTG TCC TCA GTC	1632
Ala Gln Thr Thr Val Asp Arg Asn Met Val Ala Glu Leu Ser Ser Val	
530 535 540	
TTC TTG GAC AGC TTG TAC AGC ACC GAC ACT GTC ACC CAG GGC AGC CAG	1680
Phe Leu Asp Ser Leu Tyr Ser Thr Asp Thr Val Thr Gln Gly Ser Gln	
545 550 555 560	
ATG AAT GGT TCT CCA AAA CCC CAC TGA	1707
Met Asn Gly Ser Pro Lys Pro His	
565	

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

(i) APPLICANT: Saba, Julie D.  
Zhou, Jianhui

(ii) TITLE OF INVENTION: SPHINGOSINE-1-PHOSPHATE LYASE  
POLYPEPTIDES, POLYNUCLEOTIDES AND MODULATING AGENTS AND  
METHODS OF USE THEREFOR

(iii) NUMBER OF SEQUENCES: 10

## (iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: SEED and BERRY LLP  
(B) STREET: 6300 Columbia Center, 701 Fifth Avenue  
(C) CITY: Seattle  
(D) STATE: Washington  
(E) COUNTRY: USA  
(F) ZIP: 98104

## (v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30

## (vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: US  
(B) FILING DATE: 29-SEP-1997  
(C) CLASSIFICATION:

## (viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: David, Maki J.  
(B) REGISTRATION NUMBER: 31,392  
(C) REFERENCE/DOCKET NUMBER: 200116.402

## (ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (206) 622-4900

(B) TELEFAX: (206) 682-6031

## (2) INFORMATION FOR SEQ ID NO:1:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1707 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

## (ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..1704

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

ATG CCC GGA ACC GAC CTC CTC AAG CTG AAG GAC TTC GAG CCT TAT TTG 48  
 Met Pro Gly Thr Asp Leu Leu Lys Leu Lys Asp Phe Glu Pro Tyr Leu  
 1 5 10 15

GAG ATT TTG GAA TCT TAT TCC ACA AAA GCC AAG AAT TAT GTG AAT GGA 96  
 Glu Ile Leu Glu Ser Tyr Ser Thr Lys Ala Lys Asn Tyr Val Asn Gly  
 20 25 30

TAT TGC ACC AAA TAT GAG CCC TGG CAG CTC ATT GCG TGG AGT GTC CTG 144  
 Tyr Cys Thr Lys Tyr Glu Pro Trp Gln Leu Ile Ala Trp Ser Val Leu  
 35 40 45

TGT ACT CTG CTG ATA GTC TGG GTG TAT GAG CTT ATC TTC CAG CCA GAG 192  
 Cys Thr Leu Leu Ile Val Trp Val Tyr Glu Leu Ile Phe Gln Pro Glu

50	55	60	
AGT TTA TGG TCT CGG TTT AAA AAA AAA TTA TTT AAG CTT ATC AGG AAG			240
Ser Leu Trp Ser Arg Phe Lys Lys Lys Leu Phe Lys Leu Ile Arg Lys			
65	70	75	80
ATG CCA TTT ATT GGA CGT AAG ATC GAA CAA CAG GTG AGC AAA GCC AAG			288
Met Pro Phe Ile Gly Arg Lys Ile Glu Gln Gln Val Ser Lys Ala Lys			
85	90	95	
AAG GAT CTT GTC AAG AAC ATG CCA TTC CTA AAG GTG GAC AAG GAT TAT			336
Lys Asp Leu Val Lys Asn Met Pro Phe Leu Lys Val Asp Lys Asp Tyr			
100	105	110	
GTG AAA ACT CTG CCT GCT CAG GGT ATG GGC ACA GCT GAG GTT CTG GAG			384
Val Lys Thr Leu Pro Ala Gln Gly Met Gly Thr Ala Glu Val Leu Glu			
115	120	125	
AGA CTC AAG GAG TAC AGC TCC ATG GAT GGT TCC TGG CAA GAA GGG AAA			432
Arg Leu Lys Glu Tyr Ser Ser Met Asp Gly Ser Trp Gln Glu Gly Lys			
130	135	140	
GCC TCA GGA GCT GTG TAC AAT GGG GAA CCG AAG CTC ACG GAG CTG CTG			480
Ala Ser Gly Ala Val Tyr Asn Gly Glu Pro Lys Leu Thr Glu Leu Leu			
145	150	155	160
GTG CAG GCT TAT GGA GAA TTC ACG TGG AGC AAT CCA CTG CAT CCA GAT			528
Val Gln Ala Tyr Gly Glu Phe Thr Trp Ser Asn Pro Leu His Pro Asp			
165	170	175	
ATC TTC CCT GGA TTG CGG AAG TTA GAG GCA GAA ATC GTT AGG ATG ACT			576
Ile Phe Pro Gly Leu Arg Lys Leu Glu Ala Glu Ile Val Arg Met Thr			
180	185	190	
TGT TCC CTC TTC AAT GGG GGA CCA GAT TCC TGT GGA TGT GTG ACT TCT			624
Cys Ser Leu Phe Asn Gly Gly Pro Asp Ser Cys Gly Cys Val Thr Ser			
195	200	205	

GGG GGA ACG GAA AGC ATC CTG ATG GCC TGC AAA GCT TAC CGG GAC TTG	672
Gly Gly Thr Glu Ser Ile Leu Met Ala Cys Lys Ala Tyr Arg Asp Leu	
210 215 220	
GCG TTA GAG AAG GGG ATC AAA ACT CCA GAA ATT GTG GCT CCC GAG AGT	720
Ala Leu Glu Lys Gly Ile Lys Thr Pro Glu Ile Val Ala Pro Glu Ser	
225 230 235 240	
GCC CAT GCT GCA TTC GAC AAA GCA GCT CAT TAT TTT GGG ATG AAG ATT	768
Ala His Ala Ala Phe Asp Lys Ala Ala His Tyr Phe Gly Met Lys Ile	
245 250 255	
GTC CGA GTT GCA CTG AAA AAG AAC ATG GAG GTG GAT GTG CAG GCA ATG	816
Val Arg Val Ala Leu Lys Lys Asn Met Glu Val Asp Val Gln Ala Met	
260 265 270	
AAG AGA GCC ATC TCC AGG AAC ACA GCT ATG CTG GTC TGT TCT ACC CCA	864
Lys Arg Ala Ile Ser Arg Asn Thr Ala Met Leu Val Cys Ser Thr Pro	
275 280 285	
CAG TTT CCT CAT GGT GTG ATG GAT CCT GTC CCC GAA GTG GCC AAG TTA	912
Gln Phe Pro His Gly Val Met Asp Pro Val Pro Glu Val Ala Lys Leu	
290 295 300	
ACT GTC AGA TAT AAA ATC CCA CTC CAT GTG GAT GCT TGT CTG GGG GGC	960
Thr Val Arg Tyr Lys Ile Pro Leu His Val Asp Ala Cys Leu Gly Gly	
305 310 315 320	
TTC CTC ATT GTC TTC ATG GAG AAA GCA GGG TAC CCA CTG GAG AAA CCA	1008
Phe Leu Ile Val Phe Met Glu Lys Ala Gly Tyr Pro Leu Glu Lys Pro	
325 330 335	
TTT GAT TTC CGG GTG AAA GGT GTG ACC AGC ATT TCA GCA GAT ACT CAT	1056
Phe Asp Phe Arg Val Lys Gly Val Thr Ser Ile Ser Ala Asp Thr His	
340 345 350	

AAG TAT GGC TAT GCT CCT AAA GGT TCA TCA GTG GTG ATG TAC TCT AAC 1104  
 Lys Tyr Gly Tyr Ala Pro Lys Gly Ser Ser Val Val Met Tyr Ser Asn  
 355 360 365

GAG AAG TAC AGG ACG TAC CAG TTC TTT GTT GGT GCA GAC TGG CAA GGT 1152  
 Glu Lys Tyr Arg Thr Tyr Gln Phe Phe Val Gly Ala Asp Trp Gln Gly  
 370 375 380

GGT GTC TAC GCA TCT CCA AGC ATA GCT GGC TCA CGG CCT GGT GGC ATC 1200  
 Gly Val Tyr Ala Ser Pro Ser Ile Ala Gly Ser Arg Pro Gly Gly Ile  
 385 390 395 400

ATT GCA GCC TGT TGG GCG GCC TTG ATG CAC TTC GGT GAG AAC GGC TAT 1248  
 Ile Ala Ala Cys Trp Ala Ala Leu Met His Phe Gly Glu Asn Gly Tyr  
 405 410 415

GTT GAA GCT ACC AAA CAG ATC ATC AAA ACT GCT CGC TTC CTG AAG TCA 1296  
 Val Glu Ala Thr Lys Gln Ile Ile Lys Thr Ala Arg Phe Leu Lys Ser  
 420 425 430

GAA CTG GAA AAC ATC AAA AAC ATC TTC ATT TTC GGT GAT CCT CAA TTG 1344  
 Glu Leu Glu Asn Ile Lys Asn Ile Phe Ile Phe Gly Asp Pro Gln Leu  
 435 440 445

TCA GTT ATT GCT CTG GGA TCC AAC GAT TTT GAC ATT TAC CGA CTA TCT 1392  
 Ser Val Ile Ala Leu Gly Ser Asn Asp Phe Asp Ile Tyr Arg Leu Ser  
 450 455 460

AAT ATG ATG TCT GCT AAG GGG TGG AAT TTT AAC TAC CTG CAG TTC CCA 1440  
 Asn Met Met Ser Ala Lys Gly Trp Asn Phe Asn Tyr Leu Gln Phe Pro  
 465 470 475 480

AGA AGC ATT CAT TTC TGC ATT ACG TTA GTA CAT ACT CGG AAG CGA GTG 1488  
 Arg Ser Ile His Phe Cys Ile Thr Leu Val His Thr Arg Lys Arg Val  
 485 490 495

GCG ATC CAG TTC CTA AAG GAT ATC CGG GAA TCA GTC ACA CAA ATC ATG 1536

Ala Ile Gln Phe Leu Lys Asp Ile Arg Glu Ser Val Thr Gln Ile Met  
 500 505 510

AAG AAT CCT AAA GCT AAG ACC ACA GGA ATG GGT GCC ATC TAT GGC ATG 1584  
 Lys Asn Pro Lys Ala Lys Thr Thr Gly Met Gly Ala Ile Tyr Gly Met  
 515 520 525

GCC CAG GCA ACC ATT GAC AGG AAG CTG GTT GCA GAA ATA TCC TCC GTC 1632  
 Ala Gln Ala Thr Ile Asp Arg Lys Leu Val Ala Glu Ile Ser Ser Val  
 530 535 540

TTC TTG GAC TGC CTT TAT ACT ACG GAC CCC GTG ACT CAG GGC AAC CAG 1680  
 Phe Leu Asp Cys Leu Tyr Thr Thr Asp Pro Val Thr Gln Gly Asn Gln  
 545 550 555 560

ATG AAC GGT TCT CCA AAG CCC CGC TGA 1707  
 Met Asn Gly Ser Pro Lys Pro Arg  
 565

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 568 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Pro Gly Thr Asp Leu Leu Lys Leu Lys Asp Phe Glu Pro Tyr Leu  
 1 5 10 15

Glu Ile Leu Glu Ser Tyr Ser Thr Lys Ala Lys Asn Tyr Val Asn Gly  
 20 25 30

Tyr Cys Thr Lys Tyr Glu Pro Trp Gln Leu Ile Ala Trp Ser Val Leu  
 35 40 45  
 Cys Thr Leu Leu Ile Val Trp Val Tyr Glu Leu Ile Phe Gln Pro Glu  
 50 55 60  
 Ser Leu Trp Ser Arg Phe Lys Lys Lys Leu Phe Lys Leu Ile Arg Lys  
 65 70 75 80  
 Met Pro Phe Ile Gly Arg Lys Ile Glu Gln Gln Val Ser Lys Ala Lys  
 85 90 95  
 Lys Asp Leu Val Lys Asn Met Pro Phe Leu Lys Val Asp Lys Asp Tyr  
 100 105 110  
 Val Lys Thr Leu Pro Ala Gln Gly Met Gly Thr Ala Glu Val Leu Glu  
 115 120 125  
 Arg Leu Lys Glu Tyr Ser Ser Met Asp Gly Ser Trp Gln Glu Gly Lys  
 130 135 140  
 Ala Ser Gly Ala Val Tyr Asn Gly Glu Pro Lys Leu Thr Glu Leu Leu  
 145 150 155 160  
 Val Gln Ala Tyr Gly Glu Phe Thr Trp Ser Asn Pro Leu His Pro Asp  
 165 170 175  
 Ile Phe Pro Gly Leu Arg Lys Leu Glu Ala Glu Ile Val Arg Met Thr  
 180 185 190  
 Cys Ser Leu Phe Asn Gly Gly Pro Asp Ser Cys Gly Cys Val Thr Ser  
 195 200 205  
 Gly Gly Thr Glu Ser Ile Leu Met Ala Cys Lys Ala Tyr Arg Asp Leu  
 210 215 220  
 Ala Leu Glu Lys Gly Ile Lys Thr Pro Glu Ile Val Ala Pro Glu Ser



225	230	235	240
Ala His Ala Ala Phe Asp Lys Ala Ala His Tyr Phe Gly Met Lys Ile			
	245	250	255
Val Arg Val Ala Leu Lys Lys Asn Met Glu Val Asp Val Gln Ala Met			
	260	265	270
Lys Arg Ala Ile Ser Arg Asn Thr Ala Met Leu Val Cys Ser Thr Pro			
	275	280	285
Gln Phe Pro His Gly Val Met Asp Pro Val Pro Glu Val Ala Lys Leu			
	290	295	300
Thr Val Arg Tyr Lys Ile Pro Leu His Val Asp Ala Cys Leu Gly Gly			
305	310	315	320
Phe Leu Ile Val Phe Met Glu Lys Ala Gly Tyr Pro Leu Glu Lys Pro			
	325	330	335
Phe Asp Phe Arg Val Lys Gly Val Thr Ser Ile Ser Ala Asp Thr His			
	340	345	350
Lys Tyr Gly Tyr Ala Pro Lys Gly Ser Ser Val Val Met Tyr Ser Asn			
	355	360	365
Glu Lys Tyr Arg Thr Tyr Gln Phe Phe Val Gly Ala Asp Trp Gln Gly			
	370	375	380
Gly Val Tyr Ala Ser Pro Ser Ile Ala Gly Ser Arg Pro Gly Gly Ile			
385	390	395	400
Ile Ala Ala Cys Trp Ala Ala Leu Met His Phe Gly Glu Asn Gly Tyr			
	405	410	415
Val Glu Ala Thr Lys Gln Ile Ile Lys Thr Ala Arg Phe Leu Lys Ser			
	420	425	430

Glu Leu Glu Asn Ile Lys Asn Ile Phe Ile Phe Gly Asp Pro Gln Leu  
 435 440 445

Ser Val Ile Ala Leu Gly Ser Asn Asp Phe Asp Ile Tyr Arg Leu Ser  
 450 455 460

Asn Met Met Ser Ala Lys Gly Trp Asn Phe Asn Tyr Leu Gln Phe Pro  
 465 470 475 480

Arg Ser Ile His Phe Cys Ile Thr Leu Val His Thr Arg Lys Arg Val  
 485 490 495

Ala Ile Gln Phe Leu Lys Asp Ile Arg Glu Ser Val Thr Gln Ile Met  
 500 505 510

Lys Asn Pro Lys Ala Lys Thr Thr Gly Met Gly Ala Ile Tyr Gly Met  
 515 520 525

Ala Gln Ala Thr Ile Asp Arg Lys Leu Val Ala Glu Ile Ser Ser Val  
 530 535 540

Phe Leu Asp Cys Leu Tyr Thr Thr Asp Pro Val Thr Gln Gly Asn Gln  
 545 550 555 560

Met Asn Gly Ser Pro Lys Pro Arg  
 565

(2) INFORMATION FOR SEQ ID NO:3:

(1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1707 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..1704

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

ATG CCT AGC ACA GAC CTT CTG ATG TTG AAG GCC TTT GAG CCC TAC TTA	48
Met Pro Ser Thr Asp Leu Leu Met Leu Lys Ala Phe Glu Pro Tyr Leu	
1 5 10 15	
GAG ATT TTG GAA GTA TAC TCC ACA AAA GCC AAG AAT TAT GTA AAT GGA	96
Glu Ile Leu Glu Val Tyr Ser Thr Lys Ala Lys Asn Tyr Val Asn Gly	
20 25 30	
CAT TGC ACC AAG TAT GAG CCC TGG CAG CTA ATT GCA TGG AGT GTC GTG	144
His Cys Thr Lys Tyr Glu Pro Trp Gln Leu Ile Ala Trp Ser Val Val	
35 40 45	
TGG ACC CTG CTG ATA GTC TGG GGA TAT GAG TTT GTC TTC CAG CCA GAG	192
Trp Thr Leu Leu Ile Val Trp Gly Tyr Glu Phe Val Phe Gln Pro Glu	
50 55 60	
AGT TTA TGG TCA AGG TTT AAA AAG AAA TGT TTT AAG CTC ACC AGG AAG	240
Ser Leu Trp Ser Arg Phe Lys Lys Lys Cys Phe Lys Leu Thr Arg Lys	
65 70 75 80	
ATG CCC ATT ATT GGT CGT AAG ATT CAA GAC AAG TTG AAC AAG ACC AAG	288
Met Pro Ile Ile Gly Arg Lys Ile Gln Asp Lys Leu Asn Lys Thr Lys	
85 90 95	
GAT GAT ATT AGC AAG AAC ATG TCA TTC CTG AAA GTG GAC AAA GAG TAT	336
Asp Asp Ile Ser Lys Asn Met Ser Phe Leu Lys Val Asp Lys Glu Tyr	
100 105 110	
GTG AAA GCT TTA CCC TCC CAG GGT CTG AGC TCA TCT GCT GTT TTG GAG	384

Val Lys Ala Leu Pro Ser Gln Gly Leu Ser Ser Ser Ala Val Leu Glu  
 115 120 125

AAA CTT AAG GAG TAC AGC TCT ATG GAC GCC TTC TGG CAA GAG GGG AGA 432  
 Lys Leu Lys Glu Tyr Ser Ser Met Asp Ala Phe Trp Gln Glu Gly Arg  
 130 135 140

GCC TCT GGA ACA GTG TAC AGT GGG GAG GAG AAG CTC ACT GAG CTC CTT 480  
 Ala Ser Gly Thr Val Tyr Ser Gly Glu Glu Lys Leu Thr Glu Leu Leu  
 145 150 155 160

GTG AAG GCT TAT GGA GAT TTT GCA TGG AGT AAC CCC CTG CAT CCA GAT 528  
 Val Lys Ala Tyr Gly Asp Phe Ala Trp Ser Asn Pro Leu His Pro Asp  
 165 170 175

ATC TTC CCA GGA CTA CGC AAG ATA GAG GCA GAA ATT GTG AGG ATA GCT 576  
 Ile Phe Pro Gly Leu Arg Lys Ile Glu Ala Glu Ile Val Arg Ile Ala  
 180 185 190

TGT TCC CTG TTC AAT GGG GGA CCA GAT TCG TGT GGA TGT GTG ACT TCT 624  
 Cys Ser Leu Phe Asn Gly Gly Pro Asp Ser Cys Gly Cys Val Thr Ser  
 195 200 205

GGG GGA ACA GAA AGC ATA CTC ATG GCC TGC AAA GCA TGT CGG GAT CTG 672  
 Gly Gly Thr Glu Ser Ile Leu Met Ala Cys Lys Ala Cys Arg Asp Leu  
 210 215 220

GCC TTT GAG AAG GGG ATC AAA ACT CCA GAA ATT GTG GCT CCC CAA AGT 720  
 Ala Phe Glu Lys Gly Ile Lys Thr Pro Glu Ile Val Ala Pro Gln Ser  
 225 230 235 240

GCC CAT GCT GCA TTT AAC AAA GCA GCC AGT TAC TTT GGG ATG AAG ATT 768  
 Ala His Ala Ala Phe Asn Lys Ala Ala Ser Tyr Phe Gly Met Lys Ile  
 245 250 255

GTG CGG GTC CCA TTG ACG AAG ATG ATG GAG GTG GAT GTG AGG GCA ATG 816  
 Val Arg Val Pro Leu Thr Lys Met Met Glu Val Asp Val Arg Ala Met

260	265	270	
AGA AGA GCT ATC TCC AGG AAC ACT GCC ATG CTC GTC TGT TCT ACC CCA			864
Arg Arg Ala Ile Ser Arg Asn Thr Ala Met Leu Val Cys Ser Thr Pro			
275	280	285	
CAG TTT CCT CAT GGT GTA ATA GAT CCT GTC CCT GAA GTG GCC AAG CTG			912
Gln Phe Pro His Gly Val Ile Asp Pro Val Pro Glu Val Ala Lys Leu			
290	295	300	
GCT GTC AAA TAC AAA ATA CCC CTT CAT GTC GAC GCT TGT CTG GGA GGC			960
Ala Val Lys Tyr Lys Ile Pro Leu His Val Asp Ala Cys Leu Gly Gly			
305	310	315	320
TTC CTC ATC GTC TTT ATG GAG AAA GCA GGA TAC CCA CTG GAG CAC CCA			1008
Phe Leu Ile Val Phe Met Glu Lys Ala Gly Tyr Pro Leu Glu His Pro			
325	330	335	
TTT GAT TTC CGG GTG AAA GGT GTA ACC AGC ATT TCA GCT GAC ACC CAT			1056
Phe Asp Phe Arg Val Lys Gly Val Thr Ser Ile Ser Ala Asp Thr His			
340	345	350	
AAG TAT GGC TAT GCC CCA AAA GGC TCA TCA TTG GTG TTG TAT AGT GAC			1104
Lys Tyr Gly Tyr Ala Pro Lys Gly Ser Ser Leu Val Leu Tyr Ser Asp			
355	360	365	
AAG AAG TAC AGG AAC TAT CAG TTC TTC GTC GAT ACA GAT TGG CAG GGT			1152
Lys Lys Tyr Arg Asn Tyr Gln Phe Phe Val Asp Thr Asp Trp Gln Gly			
370	375	380	
GGC ATC TAT GCT TCC CCA ACC ATC GCA GGC TCA CGG CCT GGT GGC ATT			1200
Gly Ile Tyr Ala Ser Pro Thr Ile Ala Gly Ser Arg Pro Gly Gly Ile			
385	390	395	400
AGC GCA GCC TGT TGG GCT GCC TTG ATG CAC TTC GGT GAG AAC GGC TAT			1248
Ser Ala Ala Cys Trp Ala Ala Leu Met His Phe Gly Glu Asn Gly Tyr			
405	410	415	

GTT GAA GCT ACC AAA CAG ATC ATC AAA ACT GCT CGC TTC CTC AAG TCA	1296
Val Glu Ala Thr Lys Gln Ile Ile Lys Thr Ala Arg Phe Leu Lys Ser	
420 425 430	
GAA CTG GAA AAT ATC AAA GGC ATC TTT GTT TTT GGG AAT CCC CAA TTG	1344
Glu Leu Glu Asn Ile Lys Gly Ile Phe Val Phe Gly Asn Pro Gln Leu	
435 440 445	
TCA CTC ATT GCT CTG GGA TCC CGT GAT TTT GAC ATC TAC CGA CTA TCA	1392
Ser Leu Ile Ala Leu Gly Ser Arg Asp Phe Asp Ile Tyr Arg Leu Ser	
450 455 460	
AAC CTG ATG ACT GCT AAG GGG TGG AAC TTG AAC CAG TTG CAG TTC CCA	1440
Asn Leu Met Thr Ala Lys Gly Trp Asn Leu Asn Gln Leu Gln Phe Pro	
465 470 475 480	
CCC AGT ATT CAT TTC TGC ATC ACA TTA CTA CAC GCC CGG AAA CGA GTA	1488
Pro Ser Ile His Phe Cys Ile Thr Leu Leu His Ala Arg Lys Arg Val	
485 490 495	
GCT ATA CAA TTC CTA AAG GAC ATT CGA GAA TCT GTC ACT CAA ATC ATG	1536
Ala Ile Gln Phe Leu Lys Asp Ile Arg Glu Ser Val Thr Gln Ile Met	
500 505 510	
AAG AAT CCT AAA GCG AAG ACC ACA GGA ATG GGT GCC ATC TAT GCC ATG	1584
Lys Asn Pro Lys Ala Lys Thr Thr Gly Met Gly Ala Ile Tyr Ala Met	
515 520 525	
GCC CAG ACA ACT GTT GAC AGG AAT ATG GTT GCA GAA TTG TCC TCA GTC	1632
Ala Gln Thr Thr Val Asp Arg Asn Met Val Ala Glu Leu Ser Ser Val	
530 535 540	
TTC TTG GAC AGC TTG TAC AGC ACC GAC ACT GTC ACC CAG GGC AGC CAG	1680
Phe Leu Asp Ser Leu Tyr Ser Thr Asp Thr Val Thr Gln Gly Ser Gln	
545 550 555 560	

ATG AAT GGT TCT CCA AAA CCC CAC TGA

1707

Met Asn Gly Ser Pro Lys Pro His

565

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 568 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met Pro Ser Thr Asp Leu Leu Met Leu Lys Ala Phe Glu Pro Tyr Leu  
1 5 10 15

Glu Ile Leu Glu Val Tyr Ser Thr Lys Ala Lys Asn Tyr Val Asn Gly  
20 25 30

His Cys Thr Lys Tyr Glu Pro Trp Gln Leu Ile Ala Trp Ser Val Val  
35 40 45

Trp Thr Leu Leu Ile Val Trp Gly Tyr Glu Phe Val Phe Gln Pro Glu  
50 55 60

Ser Leu Trp Ser Arg Phe Lys Lys Lys Cys Phe Lys Leu Thr Arg Lys  
65 70 75 80

Met Pro Ile Ile Gly Arg Lys Ile Gln Asp Lys Leu Asn Lys Thr Lys  
85 90 95

Asp Asp Ile Ser Lys Asn Met Ser Phe Leu Lys Val Asp Lys Glu Tyr  
100 105 110

WO 99/16888

Val Lys Ala Leu Pro Ser Gln Gly Leu Ser Ser Ser Ala Val Leu Glu  
 115 120 125

Lys Leu Lys Glu Tyr Ser Ser Met Asp Ala Phe Trp Gln Glu Gly Arg  
 130 135 140

Ala Ser Gly Thr Val Tyr Ser Gly Glu Glu Lys Leu Thr Glu Leu Leu  
 145 150 155 160

Val Lys Ala Tyr Gly Asp Phe Ala Trp Ser Asn Pro Leu His Pro Asp  
 165 170 175

Ile Phe Pro Gly Leu Arg Lys Ile Glu Ala Glu Ile Val Arg Ile Ala  
 180 185 190

Cys Ser Leu Phe Asn Gly Gly Pro Asp Ser Cys Gly Cys Val Thr Ser  
 195 200 205

Gly Gly Thr Glu Ser Ile Leu Met Ala Cys Lys Ala Cys Arg Asp Leu  
 210 215 220

Ala Phe Glu Lys Gly Ile Lys Thr Pro Glu Ile Val Ala Pro Gln Ser  
 225 230 235 240

Ala His Ala Ala Phe Asn Lys Ala Ala Ser Tyr Phe Gly Met Lys Ile  
 245 250 255

Val Arg Val Pro Leu Thr Lys Met Met Glu Val Asp Val Arg Ala Met  
 260 265 270

Arg Arg Ala Ile Ser Arg Asn Thr Ala Met Leu Val Cys Ser Thr Pro  
 275 280 285

Gln Phe Pro His Gly Val Ile Asp Pro Val Pro Glu Val Ala Lys Leu  
 290 295 300

Ala Val Lys Tyr Lys Ile Pro Leu His Val Asp Ala Cys Leu Gly Gly



305	310	315	320
Phe Leu Ile Val	Phe Met Glu Lys Ala Gly Tyr Pro	Leu Glu His Pro	
325	330	335	
Phe Asp Phe Arg Val	Lys Gly Val Thr Ser Ile Ser	Ala Asp Thr His	
340	345	350	
Lys Tyr Gly Tyr Ala Pro	Lys Gly Ser Ser Leu Val	Leu Tyr Ser Asp	
355	360	365	
Lys Lys Tyr Arg Asn Tyr	Gln Phe Phe Val Asp Thr Asp	Trp Gln Gly	
370	375	380	
Gly Ile Tyr Ala Ser Pro	Thr Ile Ala Gly Ser Arg Pro	Gly Gly Ile	
385	390	395	400
Ser Ala Ala Cys Trp Ala	Ala Leu Met His Phe Gly Glu	Asn Gly Tyr	
405	410	415	
Val Glu Ala Thr Lys Gln	Ile Ile Lys Thr Ala Arg Phe	Leu Lys Ser	
420	425	430	
Glu Leu Glu Asn Ile Lys	Gly Ile Phe Val Phe Gly Asn	Pro Gln Leu	
435	440	445	
Ser Leu Ile Ala Leu Gly	Ser Arg Asp Phe Asp Ile Tyr	Arg Leu Ser	
450	455	460	
Asn Leu Met Thr Ala Lys	Gly Trp Asn Leu Asn Gln	Leu Gln Phe Pro	
465	470	475	480
Pro Ser Ile His Phe Cys	Ile Thr Leu Leu His Ala	Arg Lys Arg Val	
485	490	495	
Ala Ile Gln Phe Leu Lys	Asp Ile Arg Glu Ser Val Thr	Gln Ile Met	
500	505	510	

Lys Asn Pro Lys Ala Lys Thr Thr Gly Met Gly Ala Ile Tyr Ala Met  
 515 520 525

Ala Gln Thr Thr Val Asp Arg Asn Met Val Ala Glu Leu Ser Ser Val  
 530 535 540

Phe Leu Asp Ser Leu Tyr Ser Thr Asp Thr Val Thr Gln Gly Ser Gln  
 545 550 555 560

Met Asn Gly Ser Pro Lys Pro His  
 565

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1629 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..1626

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

ATG GAT TTT GCA CTG GAG CAA TAT CAT AGT GCA AAG GAT TTG TTA ATA 48  
 Met Asp Phe Ala Leu Glu Gln Tyr His Ser Ala Lys Asp Leu Leu Ile  
 1 5 10 15

TTT GAG CTT CGA AAG TTC AAT CCA ATT GTT CTG GTT TCT AGT ACT ATT 96  
 Phe Glu Leu Arg Lys Phe Asn Pro Ile Val Leu Val Ser Ser Thr Ile  
 20 25 30

GTT GCA ACA TAC GTA CTC ACC AAT CTG AGA CAT ATG CAT TTA GAT GAA	144
Val Ala Thr Tyr Val Leu Thr Asn Leu Arg His Met His Leu Asp Glu	
35 40 45	
ATG GGC ATC CGG AAA CGT TTG AGC ACT TGG TTT TTC ACC ACT GTA AAG	192
Met Gly Ile Arg Lys Arg Leu Ser Thr Trp Phe Phe Thr Thr Val Lys	
50 55 60	
CGT GTG CCT TTC ATC AGG AAA ATG ATT GAC AAA CAA CTA AAC GAA GTA	240
Arg Val Pro Phe Ile Arg Lys Met Ile Asp Lys Gln Leu Asn Glu Val	
65 70 75 80	
AAG GAC GAG CTT GAG AAA AGT CTG AGA ATT GTG GAT CGA AGC ACC GAA	288
Lys Asp Glu Leu Glu Lys Ser Leu Arg Ile Val Asp Arg Ser Thr Glu	
85 90 95	
TAC TTC ACT ACA ATC CCA AGC CAT TCA GTT GGA AGA ACT GAA GTA CTT	336
Tyr Phe Thr Thr Ile Pro Ser His Ser Val Gly Arg Thr Glu Val Leu	
100 105 110	
CGC CTT GCT GCC ATC TAT GAT GAT TTG GAA GGA CCA GCT TTT TTG GAA	384
Arg Leu Ala Ala Ile Tyr Asp Asp Leu Glu Gly Pro Ala Phe Leu Glu	
115 120 125	
GGA AGA GTA TCT GGA GCA GTC TTC AAT AGA GAA GAC GAC AAG GAC GAA	432
Gly Arg Val Ser Gly Ala Val Phe Asn Arg Glu Asp Asp Lys Asp Glu	
130 135 140	
CGG GAG ATG TAT GAG GAG GTG TTC GGA AAA TTT GCC TGG ACC AAC CCA	480
Arg Glu Met Tyr Glu Glu Val Phe Gly Lys Phe Ala Trp Thr Asn Pro	
145 150 155 160	
CTT TGG CCA AAA TTG TTC CCT GGA GTG AGA ATC ATG GAG GCT GAA GTT	528
Leu Trp Pro Lys Leu Phe Pro Gly Val Arg Ile Met Glu Ala Glu Val	
165 170 175	

GTT CGC ATG TGT TGT AAT ATG ATG AAT GGA GAT TCG GAG ACA TGT GGA	576
Val Arg Met Cys Cys Asn Met Met Asn Gly Asp Ser Glu Thr Cys Gly	
180 185 190	
ACT ATG TCA ACT GGT GGA TCC ATT TCA ATT CTT TTG GCG TGC CTG GCT	624
Thr Met Ser Thr Gly Gly Ser Ile Ser Ile Leu Leu Ala Cys Leu Ala	
195 200 205	
CAT CGT AAT CGT CTT TTG AAA AGA GGA GAA AAG TAC ACA GAG ATG ATT	672
His Arg Asn Arg Leu Leu Lys Arg Gly Glu Lys Tyr Thr Glu Met Ile	
210 215 220	
GTC CCA TCA TCC GTC CAT GCA GCG TTC TTC AAA GCT GCC GAA TGT TTC	720
Val Pro Ser Ser Val His Ala Ala Phe Phe Lys Ala Ala Glu Cys Phe	
225 230 235 240	
CGT ATC AAA GTT CGC AAG ATT CCA GTT GAT CCT GTT ACT TTC AAA GTA	768
Arg Ile Lys Val Arg Lys Ile Pro Val Asp Pro Val Thr Phe Lys Val	
245 250 255	
GAC CTT GTC AAA ATG AAA GCC GCA ATT AAC AAG AGA ACA TGT ATG TTA	816
Asp Leu Val Lys Met Lys Ala Ala Ile Asn Lys Arg Thr Cys Met Leu	
260 265 270	
GTT GGA TCT GCT CCA AAC TTT CCA TTT GGA ACT GTT GAT GAC ATT GAA	864
Val Gly Ser Ala Pro Asn Phe Pro Phe Gly Thr Val Asp Asp Ile Glu	
275 280 285	
GCT ATT GGA CAG CTA GGA CTT GAA TAT GAC ATC CCA GTT CAT GTT GAT	912
Ala Ile Gly Gln Leu Gly Leu Glu Tyr Asp Ile Pro Val His Val Asp	
290 295 300	
GCT TGT CTT GGT GGT TTC CTT CTT CCA TTC CTT GAA GAA GAC GAG ATT	960
Ala Cys Leu Gly Gly Phe Leu Leu Pro Phe Leu Glu Glu Asp Glu Ile	
305 310 315 320	
CGC TAT GAC TTC CGT GTT CCT GGT GTA TCT TCG ATT TCT GCA GAT AGT	1008

Arg Tyr Asp Phe Arg Val Pro Gly Val Ser Ser Ile Ser Ala Asp Ser	
325 330 335	
CAC AAA TAC GGA CTC GCT CCA AAG GGG TCA TCA GTT GTT CTT TAT CGC	1056
His Lys Tyr Gly Leu Ala Pro Lys Gly Ser Ser Val Val Leu Tyr Arg	
340 345 350	
AAT AAG GAA CTT CTT CAT AAT CAG TAC TTC TGT GAT GCT GAT TGG CAA	1104
Asn Lys Glu Leu Leu His Asn Gln Tyr Phe Cys Asp Ala Asp Trp Gln	
355 360 365	
GGA GGT ATC TAT GCA TCG GCT ACT ATG GAA GGA TCA CGC GCT GGG CAC	1152
Gly Gly Ile Tyr Ala Ser Ala Thr Met Glu Gly Ser Arg Ala Gly His	
370 375 380	
AAC ATT GCA CTT TGC TGG GCC GCA ATG CTT TAT CAC GCT CAG GAA GGA	1200
Asn Ile Ala Leu Cys Trp Ala Ala Met Leu Tyr His Ala Gln Glu Gly	
385 390 395 400	
TAC AAG GCC AAT GCT AGA AAG ATT GTT GAC ACT ACA AGA AAG ATT AGA	1248
Tyr Lys Ala Asn Ala Arg Lys Ile Val Asp Thr Thr Arg Lys Ile Arg	
405 410 415	
AAT GGA CTT TCA AAC ATT AAG GGA ATC AAA TTA CAA GGG CCA AGT GAT	1296
Asn Gly Leu Ser Asn Ile Lys Gly Ile Lys Leu Gln Gly Pro Ser Asp	
420 425 430	
GTT TGT ATT GTT AGC TGG ACA ACC AAT GAT GGA GTT GAA CTC TAC AGA	1344
Val Cys Ile Val Ser Trp Thr Thr Asn Asp Gly Val Glu Leu Tyr Arg	
435 440 445	
TTC CAT AAC TTC ATG AAG GAA AAA CAT TGG CAA CTG AAT GGA CTT CAA	1392
Phe His Asn Phe Met Lys Glu Lys His Trp Gln Leu Asn Gly Leu Gln	
450 455 460	
TTC CCA GCT GGA GTT CAT ATC ATG GTC ACT ATG AAT CAT ACT CAT CCT	1440
Phe Pro Ala Gly Val His Ile Met Val Thr Met Asn His Thr His Pro	

(2) INFORMATION FOR SEQ ID NO:6:

(A) LENGTH: 542 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Met Asp Phe Ala Leu Glu Gln Tyr His Ser Ala Lys Asp Leu Leu Ile  
1 5 10 15

Phe Glu Leu Arg Lys Phe Asn Pro Ile Val Leu Val Ser Ser Thr Ile  
20 25 30

Val Ala Thr Tyr Val Leu Thr Asn Leu Arg His Met His Leu Asp Glu

35

40

45

Met Gly Ile Arg Lys Arg Leu Ser Thr Trp Phe Phe Thr Thr Val Lys

50

55

60

Arg Val Pro Phe Ile Arg Lys Met Ile Asp Lys Gln Leu Asn Glu Val

65

70

75

80

Lys Asp Glu Leu Glu Lys Ser Leu Arg Ile Val Asp Arg Ser Thr Glu

85

90

95

Tyr Phe Thr Thr Ile Pro Ser His Ser Val Gly Arg Thr Glu Val Leu

100

105

110

Arg Leu Ala Ala Ile Tyr Asp Asp Leu Glu Gly Pro Ala Phe Leu Glu

115

120

125

Gly Arg Val Ser Gly Ala Val Phe Asn Arg Glu Asp Asp Lys Asp Glu

130

135

140

Arg Glu Met Tyr Glu Glu Val Phe Gly Lys Phe Ala Trp Thr Asn Pro

145

150

155

160

Leu Trp Pro Lys Leu Phe Pro Gly Val Arg Ile Met Glu Ala Glu Val

165

170

175

Val Arg Met Cys Cys Asn Met Met Asn Gly Asp Ser Glu Thr Cys Gly

180

185

190

Thr Met Ser Thr Gly Gly Ser Ile Ser Ile Leu Leu Ala Cys Leu Ala

195

200

205

His Arg Asn Arg Leu Leu Lys Arg Gly Glu Lys Tyr Thr Glu Met Ile

210

215

220

Val Pro Ser Ser Val His Ala Ala Phe Phe Lys Ala Ala Glu Cys Phe  
 225 230 235 240  
 Arg Ile Lys Val Arg Lys Ile Pro Val Asp Pro Val Thr Phe Lys Val  
 245 250 255  
 Asp Leu Val Lys Met Lys Ala Ala Ile Asn Lys Arg Thr Cys Met Leu  
 260 265 270  
 Val Gly Ser Ala Pro Asn Phe Pro Phe Gly Thr Val Asp Asp Ile Glu  
 275 280 285  
 Ala Ile Gly Gln Leu Gly Leu Glu Tyr Asp Ile Pro Val His Val Asp  
 290 295 300  
 Ala Cys Leu Gly Gly Phe Leu Leu Pro Phe Leu Glu Glu Asp Glu Ile  
 305 310 315 320  
 Arg Tyr Asp Phe Arg Val Pro Gly Val Ser Ser Ile Ser Ala Asp Ser  
 325 330 335  
 His Lys Tyr Gly Leu Ala Pro Lys Gly Ser Ser Val Val Leu Tyr Arg  
 340 345 350  
 Asn Lys Glu Leu Leu His Asn Gln Tyr Phe Cys Asp Ala Asp Trp Gln  
 355 360 365  
 Gly Gly Ile Tyr Ala Ser Ala Thr Met Glu Gly Ser Arg Ala Gly His  
 370 375 380  
 Asn Ile Ala Leu Cys Trp Ala Ala Met Leu Tyr His Ala Gln Glu Gly  
 385 390 395 400  
 Tyr Lys Ala Asn Ala Arg Lys Ile Val Asp Thr Thr Arg Lys Ile Arg  
 405 410 415  
 Asn Gly Leu Ser Asn Ile Lys Gly Ile Lys Leu Gln Gly Pro Ser Asp



420	425	430
Val Cys Ile Val Ser Trp Thr Thr Asn Asp Gly Val Glu Leu Tyr Arg		
435	440	445
Phe His Asn Phe Met Lys Glu Lys His Trp Gln Leu Asn Gly Leu Gln		
450	455	460
Phe Pro Ala Gly Val His Ile Met Val Thr Met Asn His Thr His Pro		
465	470	475
Gly Leu Ala Glu Ala Phe Val Ala Asp Cys Arg Ala Ala Val Glu Phe		
485	490	495
Val Lys Ser His Lys Pro Ser Glu Ser Asp Lys Thr Ser Glu Ala Ala		
500	505	510
Ile Tyr Gly Leu Ala Gln Ser Ile Pro Asp Arg Ser Leu Val His Glu		
515	520	525
Phe Ala His Ser Tyr Ile Asp Ala Val Tyr Ala Leu Thr Glu		
530	535	540

## (2) INFORMATION FOR SEQ ID NO:7:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1770 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..1767

ATG AGT GGA GTA TCA AAT AAA ACA GTA TCA ATT AAT GGT TGG TAT GGC 48  
Met Ser Gly Val Ser Asn Lys Thr Val Ser Ile Asn Gly Trp Tyr Gly  
1 5 10 15

ATG CCA ATT CAT TTA CTA AGG GAA GAA GGC GAC TTT GCC CAG TTT ATG 96  
Met Pro Ile His Leu Leu Arg Glu Glu Gly Asp Phe Ala Gln Phe Met  
20 25 30

ATT CTA ACC ATC AAC GAA TTA AAA ATA GCC ATA CAT GGT TAC CTC AGA 144  
Ile Leu Thr Ile Asn Glu Leu Lys Ile Ala Ile His Gly Tyr Leu Arg  
35 40 45

AAT ACC CCA TGG TAC AAC ATG TTG AAG GAT TAT TTG TTT GTG ATC TTT 192  
Asn Thr Pro Trp Tyr Asn Met Leu Lys Asp Tyr Leu Phe Val Ile Phe  
50 55 60

TGT TAC AAG CTA ATA AGT AAT TTT TTT TAT CTG TTG AAA GTT TAT GGG 240  
Cys Tyr Lys Leu Ile Ser Asn Phe Phe Tyr Leu Leu Lys Val Tyr Gly  
65 70 75 80

CCG GTG AGG TTA GCA GTG AGA ACA TAC GAG CAT AGT TCC AGA AGA TTG 288  
Pro Val Arg Leu Ala Val Arg Thr Tyr Glu His Ser Ser Arg Arg Leu  
85 90 95

TTT CGT TGG TTA TTG GAC TCA CCA TTT TTG AGG GGT ACC GTA GAA AAG 336  
Phe Arg Trp Leu Leu Asp Ser Pro Phe Leu Arg Gly Thr Val Glu Lys  
100 105 110

GAA GTC ACA AAG GTC AAA CAA TCG ATC GAA GAC GAA CTA ATT AGA TCG 384  
Glu Val Thr Lys Val Lys Gln Ser Ile Glu Asp Glu Leu Ile Arg Ser  
115 120 125

GAC TCT CAG TTA ATG AAT TTC CCA CAG TTG CCA TCC AAT GGG ATA CCT 432  
Asp Ser Gln Leu Met Asn Phe Pro Gln Leu Pro Ser Asn Gly Ile Pro

130	135	140	
CAG GAT GAT GTT ATT GAA GAG CTA AAT AAA TTG AAC GAC TTG ATA CCA			480
Gln Asp Asp Val Ile Glu Glu Leu Asn Lys Leu Asn Asp Leu Ile Pro			
145	150	155	160
CAT ACC CAA TGG AAG GAA GGA AAG GTC TCT GGT GCC GTT TAC CAC GGT			528
His Thr Gln Trp Lys Glu Gly Lys Val Ser Gly Ala Val Tyr His Gly			
165	170	175	
GGT GAT GAT TTG ATC CAC TTA CAA ACA ATC GCA TAC GAA AAA TAT TGC			576
Gly Asp Asp Leu Ile His Leu Gln Thr Ile Ala Tyr Glu Lys Tyr Cys			
180	185	190	
GTT GCC AAT CAA TTA CAT CCC GAT GTC TTT CCT GCC GTA CGT AAA ATG			624
Val Ala Asn Gln Leu His Pro Asp Val Phe Pro Ala Val Arg Lys Met			
195	200	205	
GAA TCC GAA GTG GTT TCT ATG GTT TTA AGA ATG TTT AAT GCC CCT TCT			672
Glu Ser Glu Val Val Ser Met Val Leu Arg Met Phe Asn Ala Pro Ser			
210	215	220	
GAT ACA GGT TGT GGT ACC ACA ACT TCA GGT GGT ACA GAA TCC TTG CTT			720
Asp Thr Gly Cys Gly Thr Thr Thr Ser Gly Gly Thr Glu Ser Leu Leu			
225	230	235	240
TTA GCA TGT CTG AGC GCT AAA ATG TAT GCC CTT CAT CAT CGT GGA ATC			768
Leu Ala Cys Leu Ser Ala Lys Met Tyr Ala Leu His His Arg Gly Ile			
245	250	255	
ACC GAA CCA GAA ATA ATT GCT CCC GTA ACT GCA CAT GCT GGG TTT GAC			816
Thr Glu Pro Glu Ile Ile Ala Pro Val Thr Ala His Ala Gly Phe Asp			
260	265	270	
AAA GCT GCT TAT TAC TTT GGC ATG AAG CTA CGC CAC GTG GAG CTA GAT			864
Lys Ala Ala Tyr Tyr Phe Gly Met Lys Leu Arg His Val Glu Leu Asp			
275	280	285	

CCA ACG ACA TAT CAA GTG GAC CTG GGA AAA GTG AAA AAA TTC ATC AAT 912  
 Pro Thr Thr Tyr Gln Val Asp Leu Gly Lys Val Lys Lys Phe Ile Asn  
 290 295 300

AAG AAC ACA ATT TTA CTG GTC GGT TCC GCT CCA AAC TTT CCT CAT GGT 960  
 Lys Asn Thr Ile Leu Leu Val Gly Ser Ala Pro Asn Phe Pro His Gly  
 305 310 315 320

ATT GCC GAT GAT ATT GAA GGA TTG GGT AAA ATA GCA CAA AAA TAT AAA 1008  
 Ile Ala Asp Asp Ile Glu Gly Leu Gly Lys Ile Ala Gln Lys Tyr Lys  
 325 330 335

CTT CCT TTA CAC GTC GAC AGT TGT CTA GGT TCC TTT ATT GTT TCA TTT 1056  
 Leu Pro Leu His Val Asp Ser Cys Leu Gly Ser Phe Ile Val Ser Phe  
 340 345 350

ATG GAA AAG GCT GGT TAC AAA AAT CTG CCA TTA CTT GAC TTT AGA GTC 1104  
 Met Glu Lys Ala Gly Tyr Lys Asn Leu Pro Leu Leu Asp Phe Arg Val  
 355 360 365

CCG GGA GTC ACC TCA ATA TCA TGT GAC ACT CAT AAA TAT GGA TTT GCA 1152  
 Pro Gly Val Thr Ser Ile Ser Cys Asp Thr His Lys Tyr Gly Phe Ala  
 370 375 380

CCA AAA GGC TCG TCA GTT ATA ATG TAT AGA AAC AGC GAC TTA CGA ATG 1200  
 Pro Lys Gly Ser Ser Val Ile Met Tyr Arg Asn Ser Asp Leu Arg Met  
 385 390 395 400

CAT CAG TAT TAC GTA AAT CCT GCT TGG ACT GGC GGG TTA TAT GGC TCT 1248  
 His Gln Tyr Tyr Val Asn Pro Ala Trp Thr Gly Gly Leu Tyr Gly Ser  
 405 410 415

CCT ACA TTA GCA GGG TCC AGG CCT GGT GCT ATT GTC GTA GGT TGT TGG 1296  
 Pro Thr Leu Ala Gly Ser Arg Pro Gly Ala Ile Val Val Gly Cys Trp  
 420 425 430

GCC ACT ATG GTC AAC ATG GGT GAA AAT GGG TAC ATT GAG TCG TGC CAA	1344
Ala Thr Met Val Asn Met Gly Glu Asn Gly Tyr Ile Glu Ser Cys Gln	
435 440 445	
GAA ATA GTC GGT GCA GCA ATG AAG TTT AAA AAA TAC ATC CAG GAA AAC	1392
Glu Ile Val Gly Ala Ala Met Lys Phe Lys Lys Tyr Ile Gln Glu Asn	
450 455 460	
ATT CCA GAC CTG AAT ATA ATG GGC AAC CCT AGA TAT TCA GTC ATT TCA	1440
Ile Pro Asp Leu Asn Ile Met Gly Asn Pro Arg Tyr Ser Val Ile Ser	
465 470 475 480	
TTT TCT TCA AAG ACC TTG AAC ATA CAC GAA CTA TCT GAC AGG TTG TCC	1488
Phe Ser Ser Lys Thr Leu Asn Ile His Glu Leu Ser Asp Arg Leu Ser	
485 490 495	
AAG AAA GGC TGG CAT TTC AAT GCC CTA CAA AAG CCG GTT GCA CTA CAC	1536
Lys Lys Gly Trp His Phe Asn Ala Leu Gln Lys Pro Val Ala Leu His	
500 505 510	
ATG GCC TTC ACG AGA TTG AGC GCT CAT GTT GTG GAT GAG ATC TGC GAC	1584
Met Ala Phe Thr Arg Leu Ser Ala His Val Val Asp Glu Ile Cys Asp	
515 520 525	
ATT TTA CGT ACT ACC GTG CAA GAG TTG AAG AGC GAA TCA AAT TCT AAA	1632
Ile Leu Arg Thr Thr Val Gln Glu Leu Lys Ser Glu Ser Asn Ser Lys	
530 535 540	
CCA TCC CCA GAC GGA ACT AGC GCT CTA TAT GGT GTC GCC GGG AGC GTT	1680
Pro Ser Pro Asp Gly Thr Ser Ala Leu Tyr Gly Val Ala Gly Ser Val	
545 550 555 560	
AAA ACT GCT GGC GTT GCA GAC AAA TTG ATT GTG GGA TTC CTA GAC GCA	1728
Lys Thr Ala Gly Val Ala Asp Lys Leu Ile Val Gly Phe Leu Asp Ala	
565 570 575	
TTA TAC AAG TTG GGT CCA GGA GAG GAT ACC GCC ACC AAG TAG	1770

Leu Tyr Lys Leu Gly Pro Gly Glu Asp Thr Ala Thr Lys

580

585

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 589 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Met Ser Gly Val Ser Asn Lys Thr Val Ser Ile Asn Gly Trp Tyr Gly

1

5

10

15

Met Pro Ile His Leu Leu Arg Glu Glu Gly Asp Phe Ala Gln Phe Met

20

25

30

Ile Leu Thr Ile Asn Glu Leu Lys Ile Ala Ile His Gly Tyr Leu Arg

35

40

45

Asn Thr Pro Trp Tyr Asn Met Leu Lys Asp Tyr Leu Phe Val Ile Phe

50

55

60

Cys Tyr Lys Leu Ile Ser Asn Phe Phe Tyr Leu Leu Lys Val Tyr Gly

65

70

75

80

Pro Val Arg Leu Ala Val Arg Thr Tyr Glu His Ser Ser Arg Arg Leu

85

90

95

Phe Arg Trp Leu Leu Asp Ser Pro Phe Leu Arg Gly Thr Val Glu Lys

100

105

110

Glu Val Thr Lys Val Lys Gln Ser Ile Glu Asp Glu Leu Ile Arg Ser

115	120	125
Asp Ser Gln Leu Met Asn Phe Pro Gln Leu Pro Ser Asn Gly Ile Pro		
130	135	140
Gln Asp Asp Val Ile Glu Glu Leu Asn Lys Leu Asn Asp Leu Ile Pro		
145	150	155 160
His Thr Gln Trp Lys Glu Gly Lys Val Ser Gly Ala Val Tyr His Gly		
165	170	175
Gly Asp Asp Leu Ile His Leu Gln Thr Ile Ala Tyr Glu Lys Tyr Cys		
180	185	190
Val Ala Asn Gln Leu His Pro Asp Val Phe Pro Ala Val Arg Lys Met		
195	200	205
Glu Ser Glu Val Val Ser Met Val Leu Arg Met Phe Asn Ala Pro Ser		
210	215	220
Asp Thr Gly Cys Gly Thr Thr Thr Ser Gly Gly Thr Glu Ser Leu Leu		
225	230	235 240
Leu Ala Cys Leu Ser Ala Lys Met Tyr Ala Leu His His Arg Gly Ile		
245	250	255
Thr Glu Pro Glu Ile Ile Ala Pro Val Thr Ala His Ala Gly Phe Asp		
260	265	270
Lys Ala Ala Tyr Tyr Phe Gly Met Lys Leu Arg His Val Glu Leu Asp		
275	280	285
Pro Thr Thr Tyr Gln Val Asp Leu Gly Lys Val Lys Lys Phe Ile Asn		
290	295	300
Lys Asn Thr Ile Leu Leu Val Gly Ser Ala Pro Asn Phe Pro His Gly		
305	310	315 320

Ile Ala Asp Asp Ile Glu Gly Leu Gly Lys Ile Ala Gln Lys Tyr Lys  
325 330 335

Leu Pro Leu His Val Asp Ser Cys Leu Gly Ser Phe Ile Val Ser Phe  
340 345 350

Met Glu Lys Ala Gly Tyr Lys Asn Leu Pro Leu Leu Asp Phe Arg Val  
355 360 365

Pro Gly Val Thr Ser Ile Ser Cys Asp Thr His Lys Tyr Gly Phe Ala  
370 375 380

Pro Lys Gly Ser Ser Val Ile Met Tyr Arg Asn Ser Asp Leu Arg Met  
385 390 395 400

His Gln Tyr Tyr Val Asn Pro Ala Trp Thr Gly Gly Leu Tyr Gly Ser  
405 410 415

Pro Thr Leu Ala Gly Ser Arg Pro Gly Ala Ile Val Val Gly Cys Trp  
420 425 430

Ala Thr Met Val Asn Met Gly Glu Asn Gly Tyr Ile Glu Ser Cys Gln  
435 440 445

Glu Ile Val Gly Ala Ala Met Lys Phe Lys Lys Tyr Ile Gln Glu Asn  
450 455 460

Ile Pro Asp Leu Asn Ile Met Gly Asn Pro Arg Tyr Ser Val Ile Ser  
465 470 475 480

Phe Ser Ser Lys Thr Leu Asn Ile His Glu Leu Ser Asp Arg Leu Ser  
485 490 495

Lys Lys Gly Trp His Phe Asn Ala Leu Gln Lys Pro Val Ala Leu His  
500 505 510



Met Ala Phe Thr Arg Leu Ser Ala His Val Val Asp Glu Ile Cys Asp  
 515 520 525

Ile Leu Arg Thr Thr Val Gln Glu Leu Lys Ser Glu Ser Asn Ser Lys  
 530 535 540

Pro Ser Pro Asp Gly Thr Ser Ala Leu Tyr Gly Val Ala Gly Ser Val  
 545 550 555 560

Lys Thr Ala Gly Val Ala Asp Lys Leu Ile Val Gly Phe Leu Asp Ala  
 565 570 575

Leu Tyr Lys Leu Gly Pro Gly Glu Asp Thr Ala Thr Lys  
 580 585

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1467 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..1464

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

ATG CCT AGC ACA GAC CTT CTG ATG TTG AAG GCC TTT GAG CCC TAC TTA	48
Met Pro Ser Thr Asp Leu Leu Met Leu Lys Ala Phe Glu Pro Tyr Leu	
1 5 10 15	
GAG ATT TTG GAA GTA TAC TCC ACA AAA GCC AAG AAT TAT GTA AAT GGA	96

Glu Ile Leu Glu Val Tyr Ser Thr Lys Ala Lys Asn Tyr Val Asn Gly  
 20 25 30

CAT TGC ACC AAG TAT GAG CCC TGG CAG CTA ATT GCA TGG AGT GTC GTG 144  
 His Cys Thr Lys Tyr Glu Pro Trp Gln Leu Ile Ala Trp Ser Val Val  
 35 40 45

TGG ACC CTG CTG ATA GTC TGG GGA TAT GAG TTT GTC TTC CAG CCA GAG 192  
 Trp Thr Leu Leu Ile Val Trp Gly Tyr Glu Phe Val Phe Gln Pro Glu  
 50 55 60

AGT TTA TGG TCA AGG TTT AAA AAG AAA TGT TTT AAG CTC ACC AGG AAG 240  
 Ser Leu Trp Ser Arg Phe Lys Lys Lys Cys Phe Lys Leu Thr Arg Lys  
 65 70 75 80

ATG CCC ATT ATT GGT CGT AAG ATT CAA GAC AAG TTG AAC AAG ACC AAG 288  
 Met Pro Ile Ile Gly Arg Lys Ile Gln Asp Lys Leu Asn Lys Thr Lys  
 85 90 95

GAT GAT ATT AGC AAG AAC ATG TCA TTC CTG AAA GTG GAC AAA GAG TAT 336  
 Asp Asp Ile Ser Lys Asn Met Ser Phe Leu Lys Val Asp Lys Glu Tyr  
 100 105 110

GTG AAA GCT TTA CCC TCC CAG GGT CTG AGC TCA TCT GCT GTT TTG GAG 384  
 Val Lys Ala Leu Pro Ser Gln Gly Leu Ser Ser Ser Ala Val Leu Glu  
 115 120 125

AAA CTT AAG GAG TAC AGC TCT ATG GAC GCC TTC TGG CAA GAG GGG AGA 432  
 Lys Leu Lys Glu Tyr Ser Ser Met Asp Ala Phe Trp Gln Glu Gly Arg  
 130 135 140

GCC TCT GGA ACA GTG TAC AGT GGG GAG GAG AAG CTC ACT GAG CTC CTT 480  
 Ala Ser Gly Thr Val Tyr Ser Gly Glu Glu Lys Leu Thr Glu Leu Leu  
 145 150 155 160

GTG AAG GCT TAT GGA GAT TTT GCA TGG AGT AAC CCC CTG CAT CCA GAT 528  
 Val Lys Ala Tyr Gly Asp Phe Ala Trp Ser Asn Pro Leu His Pro Asp

165	170	175	
ATC TTC CCA GGA CTA CGC AAG ATA GAG GCA GAA ATT GTG AGG ATA GCT			576
Ile Phe Pro Gly Leu Arg Lys Ile Glu Ala Glu Ile Val Arg Ile Ala			
180	185	190	
TGT TCC CTG TTC AAT GGG GGA CCA GAT TCG TGT GGA TGT GTG ACT TCT			624
Cys Ser Leu Phe Asn Gly Gly Pro Asp Ser Cys Gly Cys Val Thr Ser			
195	200	205	
GGG GGA ACA GAA AGC ATA CTC ATG GCC TGC AAA GCA TGT CGG GAT CTG			672
Gly Gly Thr Glu Ser Ile Leu Met Ala Cys Lys Ala Cys Arg Asp Leu			
210	215	220	
GCC TTT GAG AAG GGG ATC AAA ACT CCA GAA ATT GTG GCT CCC CAA AGT			720
Ala Phe Glu Lys Gly Ile Lys Thr Pro Glu Ile Val Ala Pro Gln Ser			
225	230	235	240
GCC CAT GCT GCA TTT AAC AAA GCA GCC AGT TAC TTT GGG ATG AAG ATT			768
Ala His Ala Ala Phe Asn Lys Ala Ala Ser Tyr Phe Gly Met Lys Ile			
245	250	255	
GTG CGG GTC CCA TTG ACG AAG ATG ATG GAG GTG GAT GTG AGG GCA ATG			816
Val Arg Val Pro Leu Thr Lys Met Met Glu Val Asp Val Arg Ala Met			
260	265	270	
AGA AGA GCT ATC TCC AGG AAC ACT GCC ATG CTC GTC TGT TCT ACC CCA			864
Arg Arg Ala Ile Ser Arg Asn Thr Ala Met Leu Val Cys Ser Thr Pro			
275	280	285	
CAG TTT CCT CAT GGT GTA ATA GAT CCT GTC CCT GAA GTG GCC AAG CTG			912
Gln Phe Pro His Gly Val Ile Asp Pro Val Pro Glu Val Ala Lys Leu			
290	295	300	
GCT GTC AAA TAC AAA ATA CCC CTT CAT GTC GAC GCT TGT CTG GGA GGC			960
Ala Val Lys Tyr Lys Ile Pro Leu His Val Asp Ala Cys Leu Gly Gly			
305	310	315	320

35 / 38

66

TTC TTG GAC AGC TTG TAC AGC ACC GAC ACT GTC ACC CAG GGC AGC CAG 1440  
 Phe Leu Asp Ser Leu Tyr Ser Thr Asp Thr Val Thr Gln Gly Ser Gln  
 465 470 475 480

ATG AAT GGT TCT CCA AAA CCC CAC TGA 1467  
 Met Asn Gly Ser Pro Lys Pro His  
 485

## (2) INFORMATION FOR SEQ ID NO:10:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 488 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Met Pro Ser Thr Asp Leu Leu Met Leu Lys Ala Phe Glu Pro Tyr Leu  
 1 5 10 15

Glu Ile Leu Glu Val Tyr Ser Thr Lys Ala Lys Asn Tyr Val Asn Gly  
 20 25 30

His Cys Thr Lys Tyr Glu Pro Trp Gln Leu Ile Ala Trp Ser Val Val  
 35 40 45

Trp Thr Leu Leu Ile Val Trp Gly Tyr Glu Phe Val Phe Gln Pro Glu  
 50 55 60

Ser Leu Trp Ser Arg Phe Lys Lys Lys Cys Phe Lys Leu Thr Arg Lys  
 65 70 75 80

Met Pro Ile Ile Gly Arg Lys Ile Gln Asp Lys Leu Asn Lys Thr Lys  
 85 90 95

Asp Asp Ile Ser Lys Asn Met Ser Phe Leu Lys Val Asp Lys Glu Tyr  
 100 105 110

Val Lys Ala Leu Pro Ser Gln Gly Leu Ser Ser Ser Ala Val Leu Glu  
 115 120 125

Lys Leu Lys Glu Tyr Ser Ser Met Asp Ala Phe Trp Gln Glu Gly Arg  
 130 135 140

Ala Ser Gly Thr Val Tyr Ser Gly Glu Glu Lys Leu Thr Glu Leu Leu  
 145 150 155 160

Val Lys Ala Tyr Gly Asp Phe Ala Trp Ser Asn Pro Leu His Pro Asp  
 165 170 175

Ile Phe Pro Gly Leu Arg Lys Ile Glu Ala Glu Ile Val Arg Ile Ala  
 180 185 190

Cys Ser Leu Phe Asn Gly Gly Pro Asp Ser Cys Gly Cys Val Thr Ser  
 195 200 205

Gly Gly Thr Glu Ser Ile Leu Met Ala Cys Lys Ala Cys Arg Asp Leu  
 210 215 220

Ala Phe Glu Lys Gly Ile Lys Thr Pro Glu Ile Val Ala Pro Gln Ser  
 225 230 235 240

Ala His Ala Ala Phe Asn Lys Ala Ala Ser Tyr Phe Gly Met Lys Ile  
 245 250 255

Val Arg Val Pro Leu Thr Lys Met Met Glu Val Asp Val Arg Ala Met  
 260 265 270

Arg Arg Ala Ile Ser Arg Asn Thr Ala Met Leu Val Cys Ser Thr Pro  
 275 280 285

Gln Phe Pro His Gly Val Ile Asp Pro Val Pro Glu Val Ala Lys Leu

290	295	300	
Ala Val Lys Tyr Lys Ile Pro Leu His Val Asp Ala Cys Leu Gly Gly			
305	310	315	320
Phe Leu Ile Val Phe Met Glu Lys Ala Gly Tyr Pro Leu Glu His Pro			
325	330	335	
Phe Asp Phe Arg Val Lys Gly Val Thr Ser Ile Ser Ala Asp Thr His			
340	345	350	
Lys Leu Glu Asn Ile Lys Gly Ile Phe Val Phe Gly Asn Pro Gln Leu			
355	360	365	
Ser Leu Ile Ala Leu Gly Ser Arg Asp Phe Asp Ile Tyr Arg Leu Ser			
370	375	380	
Asn Leu Met Thr Ala Lys Gly Trp Asn Leu Asn Gln Leu Gln Phe Pro			
385	390	395	400
Pro Ser Ile His Phe Cys Ile Thr Leu Leu His Ala Arg Lys Arg Val			
405	410	415	
Ala Ile Gln Phe Leu Lys Asp Ile Arg Glu Ser Val Thr Gln Ile Met			
420	425	430	
Lys Asn Pro Lys Ala Lys Thr Thr Gly Met Gly Ala Ile Tyr Ala Met			
435	440	445	
Ala Gln Thr Thr Val Asp Arg Asn Met Val Ala Glu Leu Ser Ser Val			
450	455	460	
Phe Leu Asp Ser Leu Tyr Ser Thr Asp Thr Val Thr Gln Gly Ser Gln			
465	470	475	480
Met Asn Gly Ser Pro Lys Pro His			
485			

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

WO 99/16888

(51) International Patent Classification 6 :  
C12N 15/60, 5/10, 1/21, 9/88, C12Q 1/68,  
C07K 16/40, G01N 33/50, 33/68, A61K 31/00

A3

(11) International Publication Number:

(43) International Publication Date:

8 April 1999 (08.04.99)

(21) International Application Number: PCT/US98/20365

(22) International Filing Date: 29 September 1998 (29.09.98)

(30) Priority Data: 08/939,309 29 September 1997 (29.09.97) US

(71) Applicant: CHILDREN'S HOSPITAL OAKLAND RE-  
SEARCH INSTITUTE [US/US]; 747 Fifty Second Street,  
Oakland, CA 96409-1809 (US).

(72) Inventors: SABA, Julie, D.; Apartment 7317, 6401 Bay Street,  
Emeryville, CA 95608 (US). ZHOU, Jianhui; 246 Bearritz  
Court, Redwood City, CA 94065 (US).

(74) Agents: MAKI, David, J. et al.; Seed and Berry LLP,  
6300 Columbia Center, 701 Fifth Avenue, Seattle, WA  
98104-7092 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR,  
BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE,  
GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ,  
LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW,  
MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,  
TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent  
(GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent  
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent  
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT,  
LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI,  
CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published


With international search report.

(88) Date of publication of the international search report:  
24 June 1999 (24.06.99)

(54) Title: SPHINGOSINE-1-PHOSPHATE LYASE POLYPEPTIDES, POLYNUCLEOTIDES AND MODULATING AGENTS AND  
METHODS OF USE THEREFOR

(57) Abstract

Compositions, methods and kits for diagnosing and treating  
cancer are provided. Therapeutic compositions may comprise agents  
that modulate the expression or activity of a sphingosine-1-phosphate  
lyase (SPL). Such compositions may be administered to a mammal  
afflicted with cancer. Diagnostic methods and kits may employ an  
agent suitable for detecting alterations in endogenous SPL. Such  
methods and kits may be used to detect the presence of a cancer  
or to evaluate the prognosis of a known disease. SPL polypeptides,  
polynucleotides and antibodies are also provided.





*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 98/20365

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/60 C12N5/10 C12N1/21 C12N9/88 C12O1/68  
C07K16/40 G01N33/50 G01N33/68 A61K31/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C12N C12O C07K G01N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	VAN VELDHoven P AND MANNAERTS G: "Sphingosine-Phosphate Lyase" ADV. LIPID RES., vol. 26, 1993, pages 69-98, XP002097298	1-12, 19, 20, 23, 44-47
Y	see section III in particular	13, 14, 17, 24, 27-29, 32, 35, 36
Y	WO 93 19760 A (BIOMEMBRANE INST) 14 October 1993 see abstract	13, 14, 17, 24, 27, 29, 32

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "Z" document member of the same patent family

Date of the actual completion of the international search

22 March 1999

Date of mailing of the international search report

08/04/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Lonnoy, O

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/20365

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
Y	SPIEGEL S ET AL: "Sphingosine-1-phosphate, a novel second messenger involved in cell growth regulation and signal transduction, affects growth and invasiveness of human breast cancer cells" BREAST CANCER RES TREAT, vol. 31, no. 2-3, 1994, pages 337-348, XP002097299 see abstract ---	28.35.36
X	US 5 430 169 A (BOUMENDJEL AHCENE ET AL) 4 July 1995 Y see abstract ---	19 13,17
X	DATABASE EMBL12 E.M.B.L. Databases Accession Number: T86263, 30 March 1995 HILLIER L ET AL: "Homo sapiens cDNA clone 114967" XP002097302 97.2% identity in 316bp overlap see abstract ---	1,6
X	DATABASE EMBL17 E.M.B.L. Databases Accession Number: AA338781, 18 April 1997 ADAMS M ET AL: "EST44070 Fetal brain I Homo sapiens cDNA 5' end" XP002097303 97.1% identity in 243bp overlap see abstract ---	1,6
X	DATABASE EMBL20 E.M.B.L. Databases Accession Number: AA107456, 6 November 1996 MARRA M ET AL: "The WashU-HHMI Mouse EST Project" XP002097304 100% identity in 427bp overlap see abstract ---	1,6
X	DATABASE EMBL1 E.M.B.L. Databases Accession Number: AA589412, 18 September 1997 MARRA M ET AL: "The WashU-HHMI Mouse EST Project" XP002097305 100% identity in 379bp overlap see abstract --- -/--	1,6

# INTERNATIONAL SEARCH REPORT

Int. Patent Application No.

PCT/US 98/20365

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	SABA J ET AL: "The BST1 gene of <i>Saccharomyces cerevisiae</i> is the sphingosine-1-phosphate lyase" JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 272, no. 42, 17 October 1997, pages 26087-26090, XP002097300 see the whole document	1-9
P,X	ZHOU J AND SABA J: "Identification of the First Mammalian Sphingosine Phosphate Lyase Gene and Its Functional Expression in Yeast" BIOCHEM. BIOPHYS. RES. COMMUN., vol. 242, 1998, pages 502-507, XP002097301 see the whole document	1-9
A	QIE L ET AL: "Identification of a <i>Saccharomyces</i> gene, LCB3, necessary for incorporation of exogenous long chain bases into sphingolipids" JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 272, no. 26, 27 June 1997, pages 16110-16117, XP002097443 see page 16110, column 2, line 31 - line 33	

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/20365

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 19 through 36, as far as in vivo method are concerned are directed to methods of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/compositions.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims: it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. l. Application No

PCT/US 98/20365

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9319760 A	14-10-1993	US 5260288 A	09-11-1993
		CA 2130992 A	14-10-1993
		EP 0671917 A	20-09-1995
		JP 8500816 T	30-01-1996
		US 5391800 A	21-02-1995
		US 5663404 A	02-09-1997
		US 5877167 A	02-03-1999
US 5430169 A	04-07-1995	AU 1874295 A	29-08-1995
		WO 9521848 A	17-08-1995